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ABSTRACT 
The antineoplastic properties of α,β-unsaturated ketones, such as curcumin and 
related analogs, have been investigated for a number of years. Due to the high light 
sensitivity and the low bioavailability of curcumin and its analogs, there was a need to 
modify its structural features for clinical usage as a chemotherapeutic candidate. The 
emphasis on synthetic curcumin analogs which have the 1,5-diaryl-3-oxo-1,4-pentadienyl 
pharmacophore (Figure 2-1, page 32) and its importance for eliciting antineoplastic 
activity was made from this laboratory. It was proven that one way these agents exert 
their activity is through a thiol-alkylating mechanism. In order to increase the cytotoxic 
activity of these candidate agents, three target compounds containing the 1,5-diaryl-3-
oxo-1,4-pentadienyl pharmacophore were designed by incorporating potential auxiliary 
binder groups (Figure 2-2, page 33). The auxiliary binders may display antineoplastic 
properties, or they may act only to enhance the bonding at the binding site. The synthesis 
of the auxiliary binders and the target compounds containing different physicochemical 
properties was proposed in order to investigate the structural features responsible for 
enhancing the biological activity. Both auxiliary binders 1 and the target compounds 2 
were synthesized successfully mainly through a series of condensation reactions 
(Schemes 4-1 and 4-2, pages 61-63). Following the synthesis, the biological evaluation 
was performed including multiple cytotoxicity assays59-61 as well as a multidrug 
resistance (MDR)-revertant assay62. The compounds were analyzed via 1H NMR, 13C 
NMR, and CHN elemental analyses. The biological screening of 1a, 1f, and 1g using four 
cell lines L1210, Molt4/C8, CEM, and HeLa cells revealed that they lack cytotoxic 
activity (IC50 > 100 µM, Table 4-1, page 65), and they might play a role in enhancing the 
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alignment of the target compounds to the receptor. However, other auxiliary binders also 
displayed very low cytotoxicity (IC50 > 100 µM) except for 1h (IC50 = 61 µM). The target 
compounds 2c (13.3 µM) and 2d (15.3 µM) were more potent than 2b (25.5 µM) in this 
assay.59 These data are presented in Tables 4-1 and 4-2, pages 65 and 66. The target 
compounds also displayed anti-metastasis activity towards various non-adherent cancer 
cells60 indicated on page 81. Generally, the target compounds 2b-d have selectively 
inhibited tumor growth in the micromolar and sub-micromolar range, and the highest 
potency was displayed by 2b which inhibited > 50% of non-adherent tumor cells at 1 µM. 
Two auxiliary binders inhibited more than 10% of the tumor cells at 5 µM namely, 1g 
(20%, Jurkat) and 1j (32.3%, DU145) respectively. These data are presented in Tables 4-
4 and 4-5, pages 69 and 70. The selective cytotoxicity of the target compounds 2b-d as 
well as the auxiliary binders 1 were also examined.61 Some of the auxiliary binders 
displayed cytotoxic effects at CC50 < 80 µM namely, 1c, 1f, 1h, 1j, and 1m. Compounds 
2b-d displayed potency in the range of CC50 = 14-44 µM; however, 2b is the best 
candidate compound as it exhibited high selectivity (SI up to > 30.44) to cancer cells 
compared to 2b and 2c. Moreover the target compounds 2b-d have MDR-revertant 
properties at low and high micromolar concentrations in which the established FAR 
values were > 1. Compound 2b reversed  the MDR at 50 µM (FAR = 118.15 at 50 µM) 
more that standard drug verapamil  (FAR = 15.68). For future directions, selected 
auxiliary binders will be incorporated to the 1,5-diaryl-3-oxo-1,4-pentadienyl 
pharmacophore, and the mechanism of auxiliary binding should be investigated.  
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CHAPTER 1 
1. Literature Review 
1.1 Introduction 
The term cancer was mentioned for the first time between 3000 BC and 1500 BC. 
It was written on Egyptian papyri and explained as cancer of the breast.1 The word 
“cancer”, which is derived from a Greek word meaning crab, was described in the 5th 
century BC as a group of diseases characterized by uncontrolled growth which could 
spread through the body in a life threatening way.2,3 Cancer existed thousands of years 
ago, but the incidence rate was significantly lower in contrast to the current era. For the 
last fifty years, the probability of having cancer is twice as much as previously.2 This 
situation refers to the increased acquisition of cancer-related habits such as smoking, 
unhealthy diets, and poor physical activity. Based on recent GLOBOCAN statistics, 
cancer is one of the leading causes of death globally, as it is the second and third leading 
causes in economically developed and developing countries, respectively. About 12.7 
million new cases and 7.6 million deaths were estimated to occur in 2008 worldwide, and 
this number is expected to grow to 27 million new cases and 17.5 million deaths by 
2050.4,5 Despite cancer affecting people from different races, genders, social classes, and 
nations equally, the distribution of specific cancers among countries varies based on a 
number of factors. For example, the prevalence of smoking in economically developing 
countries leads to an increase in the incidence of lung cancer. Similarly, the increased 
demand on fast foods in European countries is a cause of the increased incidence of 
colorectal cancer.6 
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1.2 Cancer Biology 
A detailed definition of cancer was given by Ruddon and colleagues as “an 
abnormal growth of cells caused by multiple changes in gene expression leading to a 
deregulated balance of cell proliferation and cell death and ultimately evolving into a 
population of cells that can invade tissues and metastasize to distant sites, causing 
significant morbidity and, if untreated, death of the host”.6 Deoxyribonucleic acid (DNA) 
is the genetic template of cells and is composed of genes. Malfunction of genes in 
different ways leads to abnormal changes in cell functions. These mutations could be 
gene deletion, amplification, translocation, or duplication.6,7 Cancer initiation and 
development require 3-7 genetic hits for common cancers, or at least two genetic hits in 
some others.8 These genetic mutations could be inherited before birth (spontaneous 
mutation), acquired after birth (somatic mutation), or both. Alternation of the expression 
of oncogenes and tumor suppressor genes results in interrupting the normal process of 
cell division and differentiation; hence this dysfunction produces new cells which prefer 
to grow abnormally while resisting death and are called tumors.6,9 However, cancer 
development is not an easy process since the affected cells undergo mechanisms which 
can repair DNA genetic damages or induce apoptosis. Abnormal growing cells can be 
classified as benign or malignant tumors. Benign tumors invade surrounding tissues 
locally, while malignant tumors have the ability to invade neighboring tissues, spread 
through the lymphatic system, and metastasize to other remote organs in the body.6 While 
each type of cancer possesses unique characteristics, even so all cancer types share the 
following features: decreased cellular differentiation, abnormal increased cellular 
proliferation, abnormal invasion ability, and the tendency to spread all through the body. 
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Cancers vary from each other in many ways because of different mutations. These factors 
are the growth rate, proliferation rate, cellular differentiation, onset age, invasion, 
metastasis, response to treatment, and prognosis. However, there are many mechanisms 
of gene mutation, either by DNA direct injury or by atypical genetic translation or 
transcription. The phenotypicity of cancer has clinical implications of how the disease is 
treated and what resistance to drug therapy may result.2 
 
1.3 Treatment Options 
A wide variety of treatment options are available for people who have been 
diagnosed with cancer based on the type and stage of the cancer. Both traditional and 
modern treatments are still applied, for example, but not limited to: radiation, 
chemotherapy, surgery, immunotherapy, targeted therapy, hypertherapy, and hormonal 
therapy. While the main goal of traditional cancer treatments is the complete removal of 
the tumor with minimal damage to surrounding normal tissues, a great deal of damage to 
normal cells generally occurs. However, novel cure therapies have shown significantly 
decreased damage to normal cells and tissues in contrast. Normally the treatment 
combines surgery followed by chemotherapy, radiation, or both as needed.  
 
1.3.1 Surgery 
Surgery is the oldest approach to cure cancer and the aim is to remove the tumor 
and terminate its spread to other organs. However, it has limitations since only non-
metastasized solid tumors can be surgically removed. Many different techniques of 
surgery have developed recently such as laser surgery and electrosurgery. Laser surgery 
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is a technique which relies on focusing a laser light beam to cut through the tumor’s 
tissue and is effective in reducing the cutting area as in traditional surgery. Laser surgery 
is applied only for certain cancers such as liver and rectal cancers. Electrosurgery is a 
technique involving the use of a high-frequency electrical current to destroy cancer cells. 
Cryosurgery techniques rely on using liquid nitrogen to freeze and kill the tumor. Many 
other techniques are also applied and used widely; overall, these techniques have 
significantly enhanced surgery efficacy and accuracy.2 
 
1.3.2 Radiation  
Radiation is a practical option to treat invaded or metastasized tumors, or even 
cancers which are difficult to be removed surgically such as in the brain. The type and 
magnitude of the radiation dose is based on the tumor location and stage. Ionized 
radiation such as high energy X rays attack DNA through free radicals which are 
generated by two different mechanisms. Reactive radicals activate the tumor protein 53 
(p53) signaling pathway and induce apoptosis or block mitosis through damaging the 
chromosomes. Radiation has a small risk of causing cancer in the future, yet modern 
approaches have helped in reducing that risk, for example, by radiation planning and 
brachytherapy. In radiation planning, a 3D picture of the tumor is taken by X rays so that 
the radiation beam is directed specifically toward the tumor region resulting in reduced 
harm to the surrounding tissues. Brachytherapy involves the use of a radiation source 
(pellets) which emit very low doses of radiation on early stage cancers. Other techniques 
are applied using drugs that work to sensitize tumors followed by radiation therapy. 
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Hyperthermia is another technique which aims to sensitize tumor cells by increasing the 
temperature of the targeted tissue by a few degrees.2  
 
1.3.3 Hormonal therapy 
Some cancers are hormone-dependent that arise in particular tissues such as breast 
tissue. Various hormones, such as estrogens and androgens, stimulate the growth of these 
cancers, i.e., breast and prostate tumors, respectively. The main aim in this kind of 
treatment is to block the hormone receptors, namely estrogen positive (ER+) in breast and 
androgen receptor (AR) in prostate cancers, using inhibitors such as tamoxifen and 
flutamide. The inhibitors compete with the hormones at the target receptor and lead to a 
block of tumor growth. Another class of drugs act in reducing the enzyme required for 
the synthesis of the hormones, for example, estrogen and androgen synthases inhibitors. 
It should be noted that these inhibitors are less toxic in comparison to DNA-targeting 
anticancer agents, because they do not have an effect on DNA replication or division of 
the cells.2,10 
 
1.3.4 Immunotherapy 
Immunotherapy was proposed in the 1800s after the observation that tumors are 
able to regress in patients with bacterial infections, in which the immune system is 
stimulated to attack the bacterial invasion, and attacks cancer cells as well. This 
observation led to the development of protein molecules produced by the body itself, 
named the cytokines. Hence the main aim of immunotherapy is to prevent tumor 
metastasis and various therapies have been developed over the last decades such as 
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lymphokines, antibodies, and vaccines. Cancer immunotherapy could be classified into 
two main classes named active immunotherapy and passive immunotherapy. Active 
immunotherapy relies on the design of immunotherapeutic agents that induce apoptosis. 
On the other hand, passive immunotherapy involves the use of the patient’s antibodies or 
other immune constituents to provide the body with the immunity to kill infections.2,11,12 
 
1.3.5 Antiangiogenesis agents 
Angiogenesis is the process in which new blood vessels grow from an established 
vasculature. It plays a significant role in normal cells as well as the growth and 
development of tumors. Developing tumors are not able to grow more than 2 mm in 
diameter without adequate supplies of nutrients and oxygen which is delivered through 
the angiogenesis process. Angiogenesis inhibitors are established as drugs and are now 
used in cancer treatment and other diseases. Bevacizumab (Avastin®) was the first 
antiangiogenesis drug developed and is used to treat many cancers such as colorectal, 
kidney, lung, and other neoplasms.2,13 
 
1.3.6 Chemotherapy 
Chemotherapy is a very widely used option and is applied to kill cancer cells by 
different mechanisms of action, basically through killing cancer cells or disrupting their 
proliferation. Chemotherapy is also applied to metastasized cancers individually or 
accompanying radiation, surgery, or both. Around 200 anticancer drugs are available 
today, and the choice of the drug is based on the cancer type and stage. Some of the 
classes of cancer chemotherapeutic drugs are: 1) alkylating and platinating agents 2) 
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antimetabolites 3) antibiotics 4) and plant-derived drugs. Alkylating agents, 
antimetabolites, and many others have distinct mechanisms of action, but in general share 
the feature of high reactivity to attack and damage DNA.2,14 Herein are three general 
mechanisms of chemotherapeutic drugs.   
 
1.3.6.1 Chemotherapeutic agents which damage the mitotic spindle 
This class of chemotherapeutic agents acts by inhibiting the development of the 
mitotic spindle found in microtubules, a cytoskeletal protein which provides the structural 
support of chromosomes. Microtubules carry the chromosomes to dividing cells through 
a particular spindle movement and consequently leads to cell division. Mitotic inhibitors 
disrupt that spindle in a way that blocks cell division. Taxanes, Vinca alkaloids, and 
colchicine are common classes of mitosis inhibitors used to treat many cancers.14 
 
1.3.6.2 Chemotherapeutic agents which block DNA synthesis  
This class of drugs functions in blocking DNA synthesis and repair through 
disrupting essential DNA synthesis metabolic pathways. These molecules could either 
bind to essential enzymes required for chromosome replication and repair, and disrupt its 
function, or it could alter the DNA or ribonucleic acid (RNA) sequence i.e., cells become 
unable to replicate chromosomes and division is blocked. The molecules structurally 
resemble substances involved in normal cellular metabolism. For example, 5-fluorouracil 
(5-FU), 6-mercaptopurine (6-MP), and methotrexate are pyrimidine, purine, and folic 
acid, antimetabolites respectively.14 
 
! 8!
 
1.3.6.3 Chemotherapeutic agents which target DNA  
 Nitrogen mustard was the first alkylating agent to be used during World War I and 
it was noted that survived soldiers who had been attacked by the gas, developed a low 
number of white blood cells. Clinical determinations revealed that nitrogen mustard 
caused remission in a lymphoma. Hence, further attempts to discover and synthesize 
other alkylating agents followed. Nowadays, there are several alkylating agents used 
effectively to treat many cancers mostly in a combination with other treatments.14 
 
 This class of drugs acts by damaging DNA through crosslinking the DNA and 
disrupting its synthesis.  They are highly reactive organic molecules and can cause 
mutagenicity and carcinogenicity. Alkylating agents attack various groups on the DNA 
molecules and modify the bases in DNA, which consequently results in affecting cellular 
functions in one of the following mechanisms based on the nature of the binding between 
the alkylating agents and the alkylated molecule:  
 
 1) Indirect DNA damaging, in which the attacked cells produce specific enzymes in 
order to repair alkylated DNA strands through cutting it out of the whole DNA. In the 
presence of a huge number of alkylated strands, chromosomes become fragmented and 
consequently malfunction.10 
 
 2) Non-permanent DNA crosslinking, in which the alkylating molecule binds to a 
DNA base preventing its normal pairing process. For example, alkylating the thymine 
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residues on DNA results in its pairing with guanine instead of adenine. Therefore, the 
DNA sequences become mutated, and the malfunctioning DNA sequences can be passed 
along to another generation of cells.10 
 
 3) Permanent DNA crosslinking, in which the alkylating molecules form a covalent 
crosslink between two strands of DNA. In the presence of many crosslinks, gene 
expression and chromosome, replication becomes blocked due to the inability of the 
strands to separate.10 
 
Despite various problems accompanying cancer chemotherapy, it has shown very 
considerable therapeutic benefits in cancer treatment for decades.  Selectivity, toxicity, 
and multidrug resistance (MDR) are related issues which lower the safety of anticancer 
drugs. The modern trend in anticancer drug design and development is focusing on 
designing molecules specifically targeting tumor cells based on the tumor profile with 
minimal damage to normal cells.  As the complete removal of the cancer without 
damaging the rest of the body is the goal of treatment, target-based drug designing is a 
rational approach for developing novel anticancer agents with high selectivity to cancer 
cells compared to normal cells.  
 
Glutathione 1 (GSH) (Figure 1-1) is a tripeptide has significant role in prevent 
cellular damage caused by reactive oxygen species. GSH contains sulfhydryl moiety 
which serves as a reducing agent for xenobiotics detoxification through formation of 
difulfide (GSSG) product. In cancer, GSH is a critical factor, that it regulates cellular 
! 10!
proliferation and apoptosis.15 Elevated levels of GSH in some tumors were reported 
which protect cancer cells and consequently lead to cells survival.16 Modulation of GSH 
levels in tumors is an approach in cancer chemotherapy.  
 
 
Figure 1-1: Glutathione structure 1 
 
In the present study, the aim is to enhance the cytotoxic potencies of some α,β-
unsaturated ketones which are thiol-selective agents, and examine the structural features 
required to maximize the biological activity through auxiliary binding.  
 
1.4 α,β-Unsaturated ketones  
1.4.1 Introduction 
Curcumin 2 (Figure 1-2) is a natural extract from the turmeric plant, the Indian 
spice used for a long time for cooking as well as for treatment purposes. In addition to its 
effect as an antineoplastic agent, curcumin also has anti-inflammatory, antioxidant, anti-
diabetic, and antiangiogenic properties.17 The biological activity of curcumin in inhibiting 
cancer cells proliferation through targeting various signaling pathways in cancer cells. 
However, due to the low oral bioavailability of curcumin, it has dimensioned its use 
clinically as a drug.18 Many efforts in modifying the structure of curcumin were 
undertaken by medicinal chemists and yielded novel cytotoxins with enhanced 
HOOC
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H
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O
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! 11!
bioavailability. These structural modifications include the synthesis of dienones19,20 
which exhibit the cytotoxic potency through targeting GSH and deplete its levels in some 
tumors.21  
 
 
Figure 1-2: curcumin structure 2 
 
Acyclic conjugated α,β-unsaturated ketones, which resemble curcumin analogs, 
are thought to exert their effects through interactions with cellular thiols (Scheme 1-1). In 
addition, conjugated enones are thiol-selective agents22, and as nucleic acids are thiol 
free, mutagenicity and carcinogenicity problems should be avoided in these agents. 
Chalcones, which are 1,3-diaryl-2-propenones, have confirmed the significance of 
conjugated α,β-unsaturated ketones in cancer chemotherapy. As a long-term project, this 
laboratory has worked on the development of a number of cyclic and acyclic conjugated 
unsaturated dienones which possess the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore. 
Many of these compounds show potent cytotoxicity and anticancer properties. This series 
of compounds was developed in order to establish a correlation between structures and 
cytotoxic potencies. Substituted and unsubstituted aryl rings with different substituents 
were introduced which altered the polarity of the electrophilic centre as well as the 
hydrophobic and steric properties of the molecules.  
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Curcumin analogs have been extensively examined for the treatment and 
prevention of cancer and other diseases. In order to enhance the cytotoxicity of the 
molecules and the selectivity towards cancer cells rather than normal cells, a sequential 
cytotoxicity strategy was proposed. 23 Designing anticancer agents with multiple sites of 
action may minimize drug resistance and enhance selectivity.24,25 
 
 
Scheme 1-1: The sequential alkylation of cellular thiols by compounds containg the 1,5-
diaryl-3-oxo-1,4-pentadienyl group 
 
1.4.2 Acyclic and cyclic α,β-unsaturated ketones  
1.4.2.1 Acyclic α,β-unsaturated ketones 
Many researchers have investigated various curcumin analogs in order to examine 
how these compounds exert their bioactivity. Lin et al. studied the effect of two synthetic 
acyclic curcumin analogs 3 (Figure 1-3) toward breast and prostate cancer cell lines. Both 
displayed greater cytotoxic potencies than curcumin itself and the IC50 values are 
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between 0.3-3.5 µM. As well, they inhibited AKT phosphorylation, downregulated 
HER/neu expression, and inhibited signal transducer and activator of transcription 3 
(STAT3) signaling. Moreover, the compounds exhibited chemopreventive properties 
through the inhibition of cancer cells growth and migration.26 
 
 
Figure 1-3: Acyclic curcumin analogs 3 
 
Appiah-Opong et al. have reported the inhibitory effect of various acyclic 
curcumin analogs on glutathione S-transferase (GST) in vitro and in vivo. The analogs 4 
(Figure 1-4) displayed greater cytotoxic potencies than curcumin itself (IC50 values of 
0.2-0.7 µM).27 
 
Figure 1-4: Acyclic curcumin analogs 4 
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1.4.2.2 Cyclic α,β-unsaturated Ketones 
Appiah-Opong et al. have also reported the inhibitory effect of various cyclic 
curcumin analogs on GST in vitro and in vivo. The analogs 5 and 6 (Figures 1-5 and 1-6) 
displayed greater cytotoxic potencies than curcumin itself (IC50 values of 0.2-0.7 µM).27 
 
 
Figure 1-5: Cyclic curcumin analogs 5 
 
 
Figure 1-6: Cyclic curcumin analogs 6 
 
1.4.3 Mannich bases 
1.4.3.1 Acyclic Mannich bases 
A series of acyclic Mannich bases, which are β-aminoketones,  was designed and 
evaluated against cancer cells. The basic compounds in series 7 and 8 (Figures 1-7 and 1-
! 15!
8) have shown anticancer and cytotoxic properties.28 In addition, they have shown high 
reaction rates towards a thiol.29 However, unwanted toxicity levels in mice were 
reported.28,30 This may be due to the cyclic enones’ flexibility.  
 
   
Figure 1-7: Acyclic Mannich bases 7 
 
  
Figure 1-8: Acyclic Mannich bases 8 
 
1.4.3.2 Cyclic Mannich bases 
1.4.3.2.1 3,5-bis(Benzylidene)-4-piperidones 
The drawback of acyclic Mannich bases led to the decision of designing cyclic 
Mannich bases which are more rigid molecules. The arylidene keto group and amine 
centre of previous molecules was retained. The flexibility was reduced by incorporating a 
piperidine ring into the structure. Additionally another arylidene group was introduced 
with a view to increase the cytotoxic potency because of the second alkylating group in 9 
O
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(CH2)4CH3R2
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O
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(Figure 1-9). The resultant enhanced cytotoxicity motivated further modifications25 
including various quaternary and non-quaternary salts 10 (Figure 1-10) which showed 
similar cytotoxic potencies. The quaternary ammonium salts may have mutagenic 
potential as they bind to the DNA minor groove.31-33  
 
 
Figure 1-9: Cyclic Mannich base 9 
 
 
Figure 1-10: Cyclic Mannich bases 10 
 
Sun el al. prepared the prodrugs of some curcumin analogs 11 (Figure 1-11). The 
analogs were treated with glutathione (GSH) and cysteine-containing dipeptides to form 
conjugate analogs. The antitumor activity was retained, but the conjugate prodrugs have 
enhanced water solubility and light stability compared to the parent analogs 12 and 13 
(Figure 1-12).34   
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Figure 1-11: Cyclic Mannich bases 11 
 
 
Figure 1-12: Adducts 12 and 13 
  
1.4.3.2.2 N-Acyl-3,5-bis(benzylidene)-4-piperidones    
Further molecular modifications were conducted on the compounds containing 
the 1,5-diaryl-3-oxo-1,4-pentadienyl group. An acyl group was introduced onto the 
piperidyl nitrogen atom based on the assumption that it might increase the potency of the 
molecules through auxiliary binding with a receptor. Also it might enhance membrane 
permeability to malignant cells by functioning as a prodrug (Scheme 1-2).35  
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Scheme 1-2: Proposed primary and auxiliary binding sites 
 
The N-Acyl groups were introduced first to the 3,5-bis(benzylidene)-4-piperidone 
14 (Figure 1-13) by incorporating an additional thiol alkylating site 15 (Figure 1-14) or 
forming a prodrug 16 (Figure 1-15). Some of the compounds in series 15 and 16 were 
screened (R1 = R2 = H) and have shown increased potencies in comparison to the non N-
acyl compounds; moreover, some of the compounds in series 15 and 16 (R1 = R2 = Cl) 
have exhibited very potent cytotoxicity with lower IC50 values than the figure for 
melphalan.32,36  
 
Figure 1-13: Cyclic Mannich bases 14 
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Figure 1-14: Cyclic Mannich bases 15 
 
 
Figure 1-15: Cyclic Mannich bases 16 
 
The importance of the 1,5-diaryl-3-oxo-1,4-pentadienyl group was shown by the 
replacement of the keto group in the free base of the Mannich base 9 (Figure 1-9) by an 
alcohol function 17 (Figure 1-14) which resulted in an increased IC50 value.36 In addition, 
the liberation of the N-acyl group of some N-acyl analogs 15 and 16 (R1 = R2 = H) 
(Figure 1-12 and 1-13) was confirmed along with other metabolites.  
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Figure 1-16: Replacement of keto group with hydroxy group in 17 
 
More investigations were made in order to examine the relative cytotoxic 
potencies of series 14 and 15 (Figures 1-13) and (Figures 1-14) in the presence of 
different groups on the ring with different electronic properties. The series of compounds 
18 (Figure 1-17) and 19 (Figure 1-18) were screened against different cancer cell lines 
and series 19 possesses increased cytotoxic potencies compared to series 18, which may 
be due to the additional alkylating site.35 It was proposed that the cytotoxic potencies of 
the molecules are influenced by the torsion angles θ between the olefinic groups and the 
aryl rings. In this case potency was increased as the θ values were elevated. The 
importance of the θ values in influencing potencies in bioevaluations has been articulated 
elsewhere.37,38 In particular, both 18e and 19e inhibited RNA and protein synthesis and 
induced apoptosis.35  
 
Figure 1-17: Cyclic Mannich bases 18 
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Figure 1-18: Cyclic Mannich bases 19 
 
In order to confirm the importance of the N-acyl groups in enhancing the 
auxiliary binding at a receptor, the analogs 9 (Fig 1-9) were synthesized with different 
bulky substituents and different basic centers 20 (Figure 1-19) and 21 (Figure 1-20).  In 
general, they show increased in vitro potency than the parent compound 9 (Figure 1-9) 
(IC50 0.52-11.5 µM). In particular, series 21 are more potent than compounds in series 20 
which may be due to increased bonding to an auxiliary binding site.39 In addition, they 
reverse P-gp associated multidrug resistance.40 Some compounds in series 21 (R1=Cl; 
R2= 4-morpholinyl) exhibited very high toxicity towards colon cancer HCC-2998 with an 
IC50 figure of less than 5 nM.39   
 
Figure 1-19: Cyclic Mannich base 20 
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Figure 1-20: Cyclic Mannich bases 21 
 
1.4.3.2.3 Other N-acyl analogs of 3,5-bis(benzylidene)-4-piperidones 
An additional study was conducted in order to examine the tolerance at the 
binding sites. Various series of compounds were designed in which the chalcone and 
cinnamoyl motifs were introduced as a N-acyl group 22a and 22b, respectively (Figure 1-
21).41 The rationale was to provide an additional alkylating site, to maximize binding to a 
receptor and to enhance the targeting of the molecules. However in general compounds 
22a and 22b were less potent in vitro than the lead compound 9 (Figure 1-9). Subsequent 
modifications led to the synthesis of compounds 22c and 22d.42,43 Many of these 
compounds were more potent than melphalan towards Molt4/C8 and CEM T-
lymphocytes and exhibited potent cytotoxicity of IC50 values less than 5 µM. From the 
point of view that human N-myristoyltransferase (hNMT) enzyme is believed to be 
involved in the myristoylation process44 and its activity in some colorectal cancers is 
greater than in the corresponding normal tissues, selected compounds in series 21 and 22 
were screened in order to examine their effect on hNMT. However no inhibition of 
! 23!
hNMT was observed at concentrations which inhibited the growth of the neoplastic and 
transformed cells.  
 
Figure 1-21: Cyclic Mannich bases 22 
 
Further studies were conducted in order to examine and increase the potential of 
the lead compounds in series 18 (Figure 1-17) and 19 (Figure 1-18) and to create 
molecules which demonstrated selective cytotoxicity toward malignant rather than 
normal cells. Based on the observation that co-administration of sodium 2-
sulfanylethanesulfonate (mesna) and anticancer drugs may cause reduced side effects to 
normal cells, a series of adducts 23 were prepared (Figure 1-22).45 In general the 
compounds in series 23 when R1 is hydrogen or the N-acyl group have lower CC50 values 
to HSC-2, HSC-4, and HL-60 tumor cell lines than melphalan. These compounds were 
less toxic towards HGF, HPC, and HPLF non-malignant cells and hence demonstrated 
selectivity to the neoplasms. On the other hand, the mesna adducts (R1= 
COCH2CH2SCH2CH2SO2OH) had higher CC50 values and less tumor-selectivity.  
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Figure 1-22: Adduct analogs 23 
 
Examining the influence of the cyclic scaffold on cytotoxic potency was also 
reported. Compound 24 (Figure 1-23), which is an acyclic analog of the cyclic compound 
23  (R1= H; R2= NO2) was prepared and displayed 20 times reduced potency in 
comparison to compound 23 (R1= H; R2=NO2). It was concluded that the retention of the 
piperidine ring is very important in terms of cytotoxicity.45  
 
 
Figure 1-23: Compound’s 23 acyclic analog 24 
 
Also, the torsion angles θ1 and θ2 were studied and in series 23 were significantly 
higher than the corresponding nitro analog 24, which may contribute to the reduced 
cytotoxicity of the acyclic analog.  
 
The importance of the nature of the cyclic scaffold was shown through series 25 
(Figure 1-24) which have a dimethylene bridge attached to carbons 1 and 5 of piperidine 
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ring. Biological screening of series 25 and bridge-free analogs 26 (Figure 1-25) revealed 
that the presence of the dimethylene bridge led to compounds with reduced cytotoxic 
potency.46  
 
 
Figure 1-24: Bridge-attached analog 25 
 
 
Figure 1-25: Bridge-free analog 26 
 
In addition to the benefits of using curcumin analogs as antitumor and 
antineoplastic agents, the effect of applying them as adjuvant chemotherapy agents has 
been studied. Kanwar et al. studied the effect of curcumin analog 27 (Figure 1-26) as an 
inhibitor of colon cancer stem-like cells which have a role in cancer recurrence. 
Curcumin analog 20 was used in combination with both 5-FU and oxaliplatin (Ox) for 
colon cancer treatment, and it showed an effective approach to prevent colon cancer 
recurrence through colon cancer stem-like cells elimination.47  
! 26!
 
 
Figure 1-26: Curcumin analog 27 
 
Faiao-Flores et al. also reported the effect of using curcumin analogs as adjuvant 
chemotherapeutic agents with paclitaxel for breast cancer treatment in vivo. It was 
concluded that the combination therapy increased apoptosis up to 40% in tumor cells 
through caspase-3 phosphorylation activation.48 Abuzeid et al. investigated the effect of a 
curcumin analog 28 namely FLLL32 (Figure 1-27), on the antitumor activity of cisplatin. 
Pre-administration of FLLL32 induced the antitumor effect and sensitized cancer cells to 
cisplatin. The compound exhibited its bioactivity through inhibiting STAT3 
phosphorylation, which consequently induced apoptosis and sensitized cancer cells to 
chemotherapy treatment.49  
 
 
Figure 1-27: The FLLL32 structure 28 
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1.4.4 Multidrug Resistance 
1.4.4.1 Introduction  
Multidrug resistance (MDR) development is a major problem in cancer 
chemotherapy and there is an urgent need for developing drugs which are capable of 
reversing MDR. The drug resistance takes place in tumor cells when the drug efflux 
increases and the intracellular concentration of the drug is diminished leading to a 
reduction of the treatment effectiveness and thereby giving rise to undesirable outcomes.  
P-gp is a member of the ABC transporters located across the cellular membrane, and is 
encoded by mdr-1 and mdr-3 genes.  It functions in transporting a wide variety of 
substrates such as ions, amino acids, proteins, and xenobiotics. The phenomenon of MDR 
might result from genetic mutations induced by the antitumor agents used in the 
treatment, or it might be due to a pre-existing resistance in the tumor to the drug. MDR-
revertants exhibit their properties by 1) binding to P-gp and thus inhibit the drug efflux, 
and 2) reducing the P-gp activity or its overexpression.50,51  
 
1.4.4.2 MDR-revertant properties of α,β-unsaturated ketones  
A number of naturally occurring curcumins and synthetic analogs, in addition to 
curcumin itself, have demonstrated their abilites to overcome drug resistance, increase 
drug accumulation in the cells, and decrease the drug efflux by various mechanisms. 
These compounds have a similarity to the curcumin pharmacophore, namely an α,β-
unsaturated group which is likely responsible for the MDR-revertant activity.  
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Limtrakul and colleagues have reported that pure curcumin 2 (Figure 1-2) and the 
naturally occurring analogs, demethoxycurcumin 29 and bisdemethoxycurcumin 30 
(Figure 1-28) have reversed human MDR activity. All three compounds have decreased 
the expression of the mdr-1 gene in KB-V1 cervical cancer cells, most significantly by 
bisdemethoxycurcumin which displayed the maximum revertant activity (Figure 1-26).52  
 
Figure 1-28: Structures of demethoxycurcumin 29 and bisdemethoxycurcumin 30 
 
Further investigation was also made to examine the effect of tetrahydrocurcumin 
31 (THC) (Figure 1-29) on three P-gp proteins; ABCB1, ABCG2, and ABCC1 using 
various human cervical carcinoma and breast cancer cells. It was found that THC 
inhibited the three P-gps hyperactivity in a dose-dependent manner by binding to the 
ABC transporter, and the accumulation of the fluorescent dye was confirmed in the 
cells.53 
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Figure 1-29: Structure of tetrahydrocurcumin 31 
 
Another study by Anuchapreeda and colleagues was carried out to investigate the 
effect of curcumin on MDR-resistance activity on human cervical carcinoma KB-V1 
cells in vitro. The study reported that pure curcumin modulated the expression and 
activity of MDR P-gp in the cells using the range of concentrations of 1-55 µM.54 Choi 
and colleagues carried out a study in order to investigate the mechanism of MDR-
revertants in the L1210 cell line. They found that mdr-1b inhibition was made through 
the inhibition of the PI3K/Akt/NF-jB signaling pathway by curcumin.55 More complex 
analogs of curcumin which exhibited MDR-revertant activity have been reported. Das 
and colleagues described a number of α,β-unsaturated ketones which possesses potent P-
gp MDR revertant activity at low micrograms per mL in murine L5178 lymphoma and 
Colo 320 colonic carcinoma cells. FAR values of higher than 1 indicate that the MDR-
reversal has taken place. For example, compound 32 (Figure 1-30) reverted MDR in both 
L5178Y/MDR-1 and Colo 320/MDR-1 cells at concentrations of 0.4 and 4 µg/mL.40  
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Figure 1-30: MDR-revertant 32 
 
Other α,β-unsaturated ketones were also reported from this laboratory as MDR-
revertants. Series 33 (Figure 1-31) in general have FAR values of ≥ 1 in both 
L5178Y/MDR-1 and Colo 320/MDR-1 assays, to some extent, in a dose-dependent 
manner. Based on these observations, it was suggested that the 3-aryl-2-propenoyl group 
is significant for the MDR-revertant activity in these compounds.56  
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Figure 1-31: MDR-revertant 33 
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1.5 Conclusion   
Chemotherapy is one of the widely used approaches in cancer treatment. It is 
aggressive toward tumors and has proven its efficacy in curing cancer for decades. The 
success of the treatment depends on many factors such as the patient’s health and the type 
of cancer. However the treatment side effects can outweigh the benefits. Hence, cancer 
researchers are working on the development of anticancer agents which can kill tumors 
without damaging healthy cells. Curcumin analogs are a class of anticancer agents which 
have multiple biological effects such as anticancer and antioxidant properties in addition 
to their inhibitory effect on some enzymes which are involved in cancer initiation and 
development. The synthetic analogs have shown encouraging anticancer and MDR-
revertant properties in cancer chemotherapy. Based on the physicochemical properties, 
the biological activity of these agents varies. A number of curcumin analogs are 
candidate anticancer drugs and further research is required in order to fulfill the demand 
for finding better chemotherapeutic agents.   
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CHAPTER 2 
2. Purpose of the project 
2.1 Rationale  
The preparation of series 1 (Figure 2-1) as candidate antineoplastic agents was 
reported from this laboratory few years ago.46 The bioevaluations towards human Molt 
4/C8 and CEM T-lymphocytes as well as murine L1210 lymphocytic leukemia cells was 
undertaken. When discussing the relative potencies in this chapter of the thesis, the 
average of the IC50 values of the compounds in these three screens are presented. Series 1 
was designed based on the hypothesis that the 1,5-diaryl-3-oxo-1,4-pentadienyl 
pharmacophore interacts at a primary binding site which is responsible for the bioactivity. 
The unsubstituted compound 1a has an IC50 value of 4.69 µM in comparison to a 
reference drug melphalan which has an average IC50 figure of 2.61 µM. Obviously the 
unsubstituted analog is a lead compound.  
 
  
Figure 2-1: Structure of series 1  
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Hence, the decision was made to investigate whether placing various substituents 
in the aryl rings could lead to analogs with increased potencies. In particular, the aim was 
to prepare compounds that could align at an auxiliary binding site in addition to 
interaction of the 1,5-diaryl-3-oxo-1,4-pentadienyl group at a primary binding site. This 
idea is illustrated in Figure 2-2. Small groups capable of binding through hydrophobic 1b 
or hydrophobic and hydrogen bonding 1c (Figure 2-2) were placed into the aryl rings 
which led to compounds having average IC50 values of 171 and 228 µM, respectively.46 
Therefore, the decision was made to place substantially more complex groups onto the 
aryl rings which may interact at auxiliary binding sites. These aryl substituents 
(designated R in Figure 2-2) are referred to subsequently as auxiliary binders. These 
auxiliary binders should contain one or more atoms or groups capable of establishing 
ionic, hydrogen, and van der Waals bonding with complementary atoms or groups in 
neoplastic cells.  
 
 
Figure 2-2: Proposed primary and auxiliary binding sites 
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Previously a project was undertaken with compounds containing the 1,5-diaryl-3-
oxo-1,4-pentadienyl pharmacophore which had an additional group or the piperidyl 
nitrogen atom which permitted supplementary bonding. Thus in series 2 (Figure 2-3), the 
compound can react at the primary binding site while in the analogs 3 (Figure 2-3), 
additional bonding by the group attached to the piperidyl nitrogen atom could take place 
at an auxiliary binding site.39 A contrast between the cytotoxic potencies of series 2 and 3 
in which the aryl substituents are identical revealed that in 48% of the comparisons, 
greater potency was demonstrated in series 3 while in 35% of the cases, equipotency was 
observed. Hence, the long-term decision was made to synthesize and evaluate compounds 
with the general formula 4 and related compounds (Figure 2-3).  
 
  
Figure 2-3: Structures of series 2, 3, and 4  
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2.2 Hypothesis  
The purpose of the present investigation is to evaluate the following suppositions: 
1) A series of candidate auxiliary binders will have low or undetectable cytotoxic 
properties per se (if the auxiliary binders display antineoplastic properties, they 
would be acting at sites far removed from the primary binding site). 
2) The potencies of cytotoxins containing the 1,5-diaryl-3-oxo-1,4-pentadienyl 
pharmacophore will be increased when linked to the auxiliary binders.  
3) The target compounds will demonstrate tumor-selectivity.  
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CHAPTER 3 
3. Syntheses and bioevaluations 
3.1 Syntheses 
3.1.1 Materials and Methods 
3.1.1.1 Synthesis of Series 1 
3.1.1.1.17 General scheme for the syntheses of the compounds 1a-c,e-g,j-l. 
A general methodology for the syntheses of the compounds 1a-c, e-g, j-l is 
presented in scheme 3-1.  
 
 
Scheme 3-1: General scheme for the synthesis of 1a-c,e-g,j-l 
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3.1.1.1.1 Synthesis of 4-(2-(diethylamino)ethoxy)benzoic acid hydrochloride (3)  
 
 
Figure 3-1: Structure of compound 3 
 
A stirred mixture of methyl 4-hydroxybenzoate (3 g, 0.02 mol), 2-chloro-N,N-
diethylethanamine hydrochloride (5.1 g, 0.03 mol), potassium carbonate (7 g, 0.05 mol), 
potassium iodide (2 g, 0.01 mol), and acetone (30 ml) was heated at ~70 °C  for 4-7 h. On 
cooling, the solid was removed by filtration and the solvent was evaporated. The residue 
was dissolved in ethyl acetate (25 ml) and the solution was washed with sodium 
hydroxide solution (20 ml, 2% w/v) and deionized water (2x20 ml). Removal of the 
solvent afforded methyl 4-(2-(diethylamino)ethoxy)benzoate as an oil which was 
dissolved in ethanol (25 ml) and added to a solution of sodium hydroxide (16 g, 0.4 mol) 
in water (20 ml). The mixture was heated at ~70°C for 2 h. The ethanol was removed in 
vacuum and the aqueous solution was acidified with hydrochloric acid (12 M) at 5-6 °C. 
The solid was collected, triturated with water (previously cooled to 5-6 °C), filtered and 
dried at 55-60 °C in a vacuum oven to give 4-(2-(diethylamino)ethoxy)benzoic acid 
hydrochloride (3.46 g, yield 64%). M.p. 170-175 °C [lit.39 m.p. 170-172 °C]. 1H NMR 
(DMSO-d6): δ 1.23 (t, 6H, 2 x CH3CH2), 3.22 (s, 4H, 2 x NCH2), 3.53 (s, 2H, CH2CH2N), 
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4.42 (s, 2H, CH2O), 7.08 (d, aryl H), 7.92 (d, 2H, aryl H), 9.80 (s, 1H, HCl).  Found C, 
56.83; H, 7.72; N, 5.03%. Anal. (C13H20ClNO3) requires C, 57.04; H, 7.36; N, 5.12%.   
 
3.1.1.1.2 Synthesis of ethyl 4-(2-(diethylamino)ethoxy)benzoate hydrochloride (1a)  
 
 
Figure 3-2: Structure of compound 1a 
 
A stirred mixture of 4-(2-(diethylamino)ethoxy)benzoic acid hydrochloride 
prepared by the literature method39  (1 g, 0.004 mol) and thionyl chloride (20 ml) was 
heated at ~70°C for 2-3 h. On cooling, the solvent was evaporated. The solid was 
dissolved in ethanol (20 ml) and the solution heated at ~70°C for 3-5 h. On cooling, the 
solvent was evaporated and the solid dried at 55-60 °C in a vacuum oven and 
recrystallized from ethanol to give ethyl 4-(2-(diethylamino)ethoxy)benzoate 
hydrochloride (1 g, yield 92%). M.p. 144-145 °C. 1H NMR (CDCl3): δ 1.39 (t, 3H, 
CH3CH2), 1.47 (d, 6H, 2 x CH3CH2), 3.25 (q, 4H, 2 x CH3CH2N), 3.48 (t, 2H, 
OCH2CH2N), 4.35 (q, CH2O), 4.63 (t, 2H, CH2COO), 6.93 (m, 2H, Aryl H), 8.02 (m, 2H, 
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Aryl H), 12.72 (s, 1H, HCl).  Found C, 59.82; H, 8.19; N, 5.57%. Anal. (C15H24ClNO3) 
requires C, 59.69; H, 8.02; N, 4.64%.  
 
3.1.1.1.3 Synthesis of methyl 4-(2-(diethylamino)ethoxy)benzoate hydrochloride (1b) 
 
 
Figure 3-3: Structure of compound 1b 
 
A stirred mixture of 4-(2-(diethylamino)ethoxy)benzoic acid hydrochloride 
prepared by the literature method39 (1 g, 0.004 mol) and thionyl chloride (20 ml) was 
heated at ~70°C for 2-3 h. On cooling, the solvent was evaporated. The solid was 
dissolved in methanol (20 ml) and the solution was heated at ~70°C for 3-5 h. On 
cooling, the solvent was evaporated and the solid was dried at 55-60 °C in a vacuum oven 
and recrystallized from methanol to give methyl 4-(2-(diethylamino)ethoxy)benzoate 
hydrochloride (1 g, yield 97%). M.p. 130-135 °C. 1H NMR (CDCl3): δ 1.46 (t, 6H, 2 x 
CH3CH2N), 3.26 (s, 4H, (CH2)2N), 3.57 (d, 4H, CH2N), 3.91 (s, 3H, CH3OCO), 4.63 (s, 
CH2O), 6.94 (d, 2H, Aryl H), 8.01 (d, 2H, Aryl H), 12.69 (s, 1H, HCl).  Found C, 57.01; 
H, 7.74; N, 4.66%. Anal. (C14H23ClNO3.5) requires C, 56.60; H, 7.75; N, 4.72%.  
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3.1.1.1.4 Synthesis of isopropyl 4-(2-(diethylamino)ethoxy)benzoate hydrochloride (1c) 
 
 
Figure 3-4: Structure of compound 1c 
 
A stirred mixture of 4-(2-(diethylamino)ethoxy)benzoic acid hydrochloride 
prepared by the literature method39 (1 g, 0.004 mol) and thionyl chloride (20 ml) was 
heated at ~70°C for 2-3 h. On cooling the solvent was evaporated. The solid was 
dissolved in isopropyl alcohol (20 ml) and the solution was heated at ~70°C for 3-5 h. On 
cooling, the solvent was evaporated and the solid was dried at 55-60 °C in a vacuum oven 
and recrystallized from isopropyl alcohol to give isopropyl 4-(2-
(diethylamino)ethoxy)benzoate hydrochloride (1 g, yield 88%). M.p. 135-140 °C. 1H 
NMR (CDCl3): δ 1.37 (d, 6H, 2 x CH3CH), 1.47 (t, 6H, 2 x CH3CH2N), 3.26 (q, 4H, 2 x 
CH3CH2N), 3.51 (s, 2H, NCH2), 4.63 (s, 2H, CH2O), 5.20 (m, 1H, CH), 6.93 (d, 2H, Aryl 
H), 8.01 (d, 2H, Aryl H), 12.38 (s, 1H, HCl).  Found C, 59.23; H, 8.24; N, 4.25%. Anal. 
(C16H27ClNO3.5) requires C, 59.10; H, 8.30; N, 4.30%.  
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3.1.1.1.5 Synthesis of ethyl 4-(3-(dimethylamino)propoxy)benzoate hydrochloride (1i) 
 
 
Figure 3-5: Structure of compound 1i 
 
A stirred mixture of 4-(3-(dimethylamino)propoxy)benzoic acid hydrochloride 
prepared by the literature method57 (1 g, 0.004 mol) and thionyl chloride (20 ml) was 
heated at ~70°C for 2-3 h. On cooling, the solvent was evaporated. The solid was 
dissolved in ethanol (20 ml) and the solution was heated at ~70°C for 3-5 h. On cooling, 
the solvent was evaporated and the solid was dried at 55-60 °C in a vacuum oven and 
recrystallized from ethanol to give ethyl 4-(3-(dimethylamino)propoxy)benzoate 
hydrochloride (1 g, yield 91%). M.p. 150-156 °C. 1H NMR (CDCl3): δ 1.38 (t, 3H, 
CH3CH2), 2.44 (s, 2H, CH2CH2CH2), 2.90 (d, 6H, 2 x CH3N), 3.29 (d, 2H, CH2N), 4.10 
(t, 2H, CH2O), 4.30 (q, 2H, CH2COO), 6.80 (d, 2H, aryl H), 8.05 (d, 2H, aryl H), 12.30 
(s, 1H, HCl). Found C, 56.29; H, 8.08; N, 4.53%. Anal. (C14H23ClNO3.5) requires C, 
56.61; H, 7.81; N, 4.86%.  
 
 
! 42!
3.1.1.1.6 Synthesis of ethyl 4-(2-(dimethylamino)ethoxy)benzoate hydrochloride (1e) 
 
 
Figure 3-6: Structure of compound 1e 
 
A stirred mixture of 4-(2-(dimethylamino)ethoxy)benzoic acid hydrochloride 
prepared by the literature method57(1 g, 0.004 mol) and thionyl chloride (20 ml) was 
heated at ~70°C for 2-3 h. On cooling, the solvent was evaporated. The solid was 
dissolved in ethanol (20 ml) and the solution was heated at ~70°C for 3-5 h. On cooling, 
the solvent was evaporated and the solid was dried at 55-60 °C in a vacuum oven and 
recrystallized from ethanol to give ethyl 4-(2-(dimethylamino)ethoxy)benzoate 
hydrochloride (1 g, 91%). M.p. 140-145 °C. 1H NMR (CDCl3): δ 1.39 (t, 3H, CH3CH2), 
3.03 (s, 6H, 2 x CH3N), 3.53 (s, 2H, CH2N), 4.53 (q, 2H, CH2COO), 4.69 (s, 2H, CH2O), 
6.90 (d, 2H, aryl H), 8.03 (d, 2H, aryl H), 12.98 (s, 1H, HCl). Found C, 56.08; H, 7.78; N, 
4.87%. Anal. (C13H20.5ClN03.25) requires C, 56.06; H, 7.43; N, 5.03%.  
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3.1.1.1.7 Synthesis of 4-(2-(piperidin-1-yl)ethoxy)benzoic acid hydrochloride (1f-
precurser) 
 
 
Figure 3-7: Structure of compound 1f-precursor  
 
A stirred mixture of methyl 4-hydroxybenzoate (6 g, 0.04 mol), 1-(2-
chloroethyl)piperidine hydrochloride (10.8 g, 0.06 mol), potassium carbonate (12 g, 0.1 
mol), potassium iodide (6 g, 0.04 mol), and acetone (100 ml) was heated at ~70°C for 4-7 
h. On cooling, the solid was removed by filtration and the solvent was evaporated. The 
residue was dissolved in ethyl acetate (50 ml) and the solution was washed with sodium 
hydroxide solution (40 ml, 2% w/v) and deionized water (2x40 ml). Removal of the 
solvent afforded methyl 4-(2-(piperidin-1-yl)ethoxy)benzoate as an oil which was 
dissolved in ethanol (50 ml) and added to a solution of sodium hydroxide (20 g, 0.4 mol) 
in water (60 ml). The mixture was heated at ~70°C for 2 h. The ethanol was removed in 
vacuum and the aqueous solution was acidified with hydrochloric acid (12 M) at 5-6 °C. 
The solid was collected, triturated with water (previously cooled to 5-6 °C), filtered and 
dried at 55-60 °C in a vacuum oven to give 4-(2-(piperidin-1-yl)ethoxy)benzoic acid 
hydrochloride (6.83 g, yield 61%). M.p. 259-262 °C. 1H NMR (D2O): δ 1.37 (t, 1H, 
piperidine protons), 1.61 (m, 3H, piperidine proton), 1.82 (d, 2H, piperidine protons), 
2.90 (m, 2H, OCH2CH2N), 3.46 (m, 4H, piperidine protons), 4.33 (q, 2H, OCH2CH2N), 
6.95 (d, 2H, aryl H), 7.88 (d, 2H, aryl H). 
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3.1.1.1.8 Synthesis of ethyl 4-(2-(piperidin-1-yl)ethoxy)benzoate hydrochloride (1f) 
 
 
Figure 3-8: Structure of compound 1f 
 
A stirred mixture of 4-(2-(piperidin-1-yl)ethoxy)benzoic acid hydrochloride (1 g, 
0.004 mol) and thionyl chloride (20 ml) was heated at ~70°C for 2-3 h. On cooling, the 
solvent was evaporated. The solid was dissolved in ethanol (20 ml) and the solution was 
heated at ~70°C for 3-5 h. On cooling, the solvent was evaporated and the solid was dried 
at 55-60 °C in a vacuum oven and recrystallized from ethanol to give ethyl 4-(2-
(piperidin-1-yl)ethoxy)benzoate hydrochloride (1 g, yield 91%). M.p. 170-173 °C. 1H 
NMR (CDCl3): δ 1.39 (t, 3H, CH3CH2), 1.90 (t, 4H, piperidine proton), 2.27 (q, 2H, 
piperidine protons), 2.80 (q, 2H, piperidine protons), 3.44 (s, 2H, piperidine protons), 
3.67 (d, 2H, OCH2CH2N), 4.35 (q, 2H, COOCH2CH3), 4.66 (s, 2H, OCH2CH2N), 6.93 (d, 
2H, aryl H), 8.02 (d, 2H, aryl H), 12.42 (s, 1H, HCl). Found C, 59.62; H, 8.06; N, 4.16%. 
Anal. (C16H25ClNO3.5) requires C, 59.47; H, 7.81; N, 4.33%.   
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3.1.1.1.9 Synthesis of 4-(2-morpholin-4-ylethoxy)benzoic acid hydrochloride (1g-
precursor) 
 
 
Figure 3-9: Structure of compound 1g-precursor 
 
A stirred mixture of methyl 4-hydroxybenzoate (5 g, 0.03 mol), 4-(2-
chloroethyl)morpholine (9.2 g, 0.05 mol), potassium carbonate (10.2 g, 0.07 mol), 
potassium iodide (2 g, 0.012 mol), and acetone (30 ml) was heated at ~70°C for 4-7 h. On 
cooling, the solid was removed by filtration and the solvent was evaporated. The residue 
was dissolved in ethyl acetate (25 ml) and the solution was washed with sodium 
hydroxide solution (20 ml, 2% w/v) and deionized water (2x20 ml). Removal of the 
solvent afforded methyl 4-(2-morpholin-4-ylethoxy)benzoate as an oil which was 
dissolved in ethanol (25 ml) and added to a solution of sodium hydroxide (8 g, 0.2 mol) 
in water (20 ml). The mixture was heated at ~70°C for 2 h. The ethanol was removed in 
vacuum and the aqueous solution was acidified with hydrochloric acid (12 M) at 5-6 °C. 
The solid was collected, triturated with water (previously cooled to 5-6 °C), filtered and 
dried at 55-60 °C in a vacuum oven to give 4-(2-morpholin-4-ylethoxy)benzoic acid 
hydrochloride (6.58 g, yield 85%). M.p. 221-225 °C. 1H NMR (D2O): δ 3.21 (q, 2H, 
morpholine protons), 3.47 (m, 2H, morpholine protons), 3.56 (t, 2H, OCH2CH2N), 3.71 
(q, 2H, morpholine protons), 4.01 (s, 2H, morpholine protons), 4.36 (t, 2H, OCH2CH2N), 
6.96 (d, 2H, aryl H), 7.87 (d, 2H, aryl H). 
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3.1.1.1.10 Synthesis of ethyl 4-(2-(morpholin-4-yl)ethoxy)benzoate hydrochloride (1g)  
 
 
Figure 3-10: Structure of compound 1g 
 
A stirred mixture of 4-(2-(morpholin-4-yl)ethoxy)benzoic acid hydrochloride (1 
g, 0.004 mol) and thionyl chloride (20 ml) was heated at ~70°C for 2-3 h. On cooling, the 
solvent was evaporated. The solid was dissolved in ethanol (20 ml) and the solution was 
heated at ~70°C for 3-5 h. On cooling, the solvent was evaporated and the solid was dried 
at 55-60 °C in a vacuum oven and recrystallized from ethanol to give ethyl 4-(2-
(morpholin-4-yl)ethoxy)benzoate hydrochloride (1 g, yield 91%). M.p. 190-194 °C. 1H 
NMR (CDCl3): δ 1.40 (t, 3H, CH3CH2), 3.07 (q, 2H, CH2COO), 3.48 (s, 2H, morpholine 
protons), 3.58 (d, 2H, morpholine protons), 4.02 (t, 2H, morpholine protons), 4.29 (d, 2H, 
morpholine protons), 4.43 (q, 2H, NCH2CH2O), 4.70 (s, 2H, OCH2CH2N), 6.90 (d, 2H, 
aryl H), 8.00 (d, 2H, aryl H), 12.72 (s, 1H, HCl). Found C, 54.68; H, 7.07; N, 4.06%. 
Anal. (C15H23.5ClNO4.75) requires C, 54.66; H, 7.19; N, 4.25%.   
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3.1.1.1.11 Synthesis of (4-(2-(diethylaminoethoxy)phenyl)(piperidin-1-yl)methanone 
hydrochloride (1d) 
 
 
Figure 3-11: Structure of compound 1d 
 
A stirred mixture of 4-(2-(diethylamino)ethoxy)benzoic acid hydrochloride 
prepared by the literature method39 (1 g, 0.0036 mol) and thionyl chloride (20 ml) was 
heated at ~70°C for 2-3 h. On cooling, the solvent was evaporated and the solid dissolved 
in 1,2 dichloroethane (10 ml). A mixture of piperidine (0.7 g, 0.01 mol) and 1,2 
dichloroethane (10 ml) was added dropwise to the acid chloride solution surrounded by 
an ice bath and stirred overnight. The solvent was removed and the residue basified with 
potassium carbonate (10%, 30 ml, w/v). The compound was extracted in ethyl acetate and 
washed with water. Hydrochloric acid gas was passed into the solution, the resultant solid 
was filtered, recrystallized from tetrahydrofuran (THF) to give (4-(2-
(diethylamino)ethoxy)phenyl)(piperidin-1-yl)methanone hydrochloride (0.84 g, yield 
68%). M.p. 155-158 °C. 1H NMR (DMSO-d6): δ 1.24 (t, 6H, 2 x CH3), 1.50 (s, 6H, 
piperidine protons), 1.61 (d, 2H, CH2N), 3.2 (s, 4H, 2 x NCH2CH3), 3.50 (s, 4H, 
piperidine protons), 4.40 (s, 2H, OCH2), 7.03 (d, 2H, aryl H), 7.36 (d, 2H, aryl H), 10.30 
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(s, 2H, HCl). Found C, 62.50; H, 8.51; N, 8.0%. Anal. (C18H29.5ClN2O2.25) requires C, 
62.50; H, 9.00; N, 8.11%.  
 
3.1.1.1.12 Synthesis of ethyl 4-(isopentyloxy)benzoate (1h) 
 
 
Figure 3-12: Structure of compound 1h 
 
A stirred mixture of 4-(isopentyloxy)benzoic acid prepared by the literature 
method51 (1 g, 0.0048 mol) and thionyl chloride (20 ml) was heated at ~70°C  for 2-3 h. 
On cooling, the solvent was evaporated. The solid was dissolved in ethanol (20 ml) and 
the solution was heated at ~70°C for 3-5 h. On cooling, the solvent was evaporated and 
the solid dried at 55-60 °C in a vacuum oven to give ethyl 4-(isopentyloxy)benzoate (0.9 
g, yield 79%). 1H NMR (CDCl3): δ 0.98 (d, 6H, 2 x CH3CH), 1.39 (t, 3H, CH3CH2COO), 
1.70 (q, 2H, CHCH2), 1.82 (sextet, 1H, CH), 4.04 (t, 2H, OCH2), 4.34 (q, 2H, 
CH3CH2OCO), 6.91 (d, 2H, aryl H), 8.00 (d, 2H, aryl H). Found C, 71.09; H, 8.77%. 
Anal. (C14H20.5O3.25) requires C, 71.41; H, 9.11%.  
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3.1.1.1.13 Synthesis of methyl 4-(isopentyloxy)benzoate (1m) 
 
 
Figure 3-13: Structure of compound 1m 
 
A stirred mixture of methyl 4-hydroxybenzoate (5 g, 0.03 mol), 1-bromo-3-
methylbutane (6.5 g, 0.04 mol), potassium carbonate (7.7 g, 0.06 mol), and potassium 
iodide (2 g, 0.01 mol) was heated at ~70°C for 4-7 h. On cooling, the solid was removed 
by filtration and the solvent was evaporated. The residue was dissolved in ethyl acetate 
(25 ml) and the solution was washed with sodium hydroxide solution (20 ml, 2% w/v) 
and deionized water (2x20 ml). Removal of the solvent afforded methyl 4-
(isopentyloxy)benzoate as an oil. (5.45 g, yield 75%). 1H NMR (CDCl3): δ 0.97 (d, 6H, 
CH3CH), 1.68 (q, 2H, CH2CH), 1.81 (m, 1H, CH), 3.89 (s, 3H, CH3OCO), 4.03 (t, 2H, 
OCH2), 6.90 (d, 2H, aryl H), 7.98 (d, 2H, aryl H). Found C, 70.65; H, 8.48 Anal. 
(C13H18O3) requires C, 70.24; H, 8.16%. 
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3.1.1.1.14 Synthesis of ethyl 3-(2-(dimethylamino)ethoxy)benzoate hydrochloride (1l) 
 
      
Figure 3-14: Structure of compound 1l 
 
A stirred mixture of 3-(2-(dimethylamino)ethoxy)benzoic acid hydrochloride 
(commercially available) (1 g, 0.004 mol) and thionyl chloride (20 ml) was heated at 
~70°C for 2-3 h. On cooling, the solvent was evaporated. The solid was dissolved in 
ethanol (20 ml) and the solution was heated at ~70°C for 3-5 h. On cooling, the solvent 
was evaporated and the solid was dried at 55-60 °C in a vacuum oven and recrystallized 
from ethanol to give ethyl 3-(2-(dimethylamino)ethoxy)benzoate hydrochloride (1.04 g, 
yield 95%). M.p. 140-144 °C. 1H NMR (CDCl3): δ 1.40 (t, 3H, CH3CH2), 2.97 (d, 6H, 2 
x CH3), 3.53 (s, 2H, NCH2), 4.38 (t, 2H, CH2OCO), 4.42 (s, 2H, OCH2), 7.14 (d, 1H, aryl 
H), 7.38 (s, 1H, aryl H), 7.56 (s, 1H, aryl H), 7.72 (d, 1H, aryl H), 13.00 (s, 1H, HCl). 
Found C, 54.09; H, 7.26; N, 4.63%. Anal. (C13H21.5ClNO3.75) requires C, 54.31; H, 7.54; 
N, 4.87%.. 
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3.1.1.1.15 Synthesis of ethyl 2-(2-(diethylamino)ethoxy)benzoate hydrochloride (1j) 
 
   
Figure 3-15: Structure of compound 1j 
 
A stirred mixture of 2-(2-(diethylamino)ethoxy)benzoic acid hydrochloride 
(commercially available) (1 g, 0.004 mol) and thionyl chloride (20 ml) was heated at 
~70°C for 2-3 h. On cooling, the solvent was evaporated. The solid was dissolved in 
ethanol (20 ml) and the solution was heated at ~70°C for 3-5 h. On cooling, the solvent 
was evaporated and the solid was dried at 55-60 °C in a vacuum oven to give ethyl 2-(2-
(diethylamino)ethoxy)benzoate hydrochloride (0.27 g, yield 24%). 1H NMR (CDCl3): δ 
1.40 (t, 3H, CH3CH2), 1.49 (s, 6H, 2 x CH2CH3), 3.30 (s, 4H, 2 x CH3CH2), 3.50 (s, 2H, 
CH2N), 4.37 (q, 2H, CH2CH2O), 4.60 (s, 2H, COOCH2), 7.12 (d, 1H, aryl H), 7.38 (t, 1H, 
aryl H), 7.55 (s, 1H, aryl H), 7.71 (d, 1H, aryl H), 12.55 (s, 1H, HCl). Found C, 57.87; H, 
8.13; N, 4.33%. Anal. (C15H25ClNO3.5) requires C, 57.91; H, 8.10; N, 4.50%.  
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3.1.1.1.16 Synthesis of ethyl 3-(2-(diethylamino)ethoxy)benzoate hydrochloride (1k) 
 
 
Figure 3-16: Structure of compound 1k 
 
A stirred mixture of 3-(2-(diethylamino)ethoxy)benzoic acid hydrochloride 
(commercially available) (1 g, 0.004 mol) and thionyl chloride (20 ml) was heated at 
~70°C for 2-3 h. On cooling, the solvent was evaporated. The solid was dissolved in 
ethanol (20 ml) and the solution was heated at ~70°C for 3-5 h. On cooling, the solvent 
was evaporated and the solid was dried at 55-60 °C in a vacuum oven to give ethyl 3-(2-
(diethylamino)ethoxy)benzoate hydrochloride (1.12 g, yield 93%). M.p. 110-111 °C. 1H 
NMR (DMSO-d6): δ 1.24 (t, 6H, 2 x CH3CH2), 1.31 (t, 3H, COOCH2CH3), 3.21 (q, 4H, 2 
x CH2N), 3.51 (d, 2H, CH2N), 4.30 (q, 2H, CH2CH2O), 4.42 (t, 2H, COOCH2), 7.29 (d, 
1H, aryl H), 7.48 (t, 2H, aryl H), 7.60 (d, 1H, aryl H), 10.22 (s, 1H, HCl). Found C, 
56.75; H, 8.19; N, 4.12%. Anal. (C15H25.5ClNO3.75) requires C, 57.08; H, 8.07; N, 4.44%.  
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3.1.1.2 Synthesis of Series 2     
3.1.1.2.1 Synthesis of (3E,5E)-3,5-bis(4-hydroxybenzylidene)-1-methylpiperidin-4-one 
(2a) 
 
 
Figure 3-17: Structure of compound 2a 
 
A stirred mixture of 4-hydroxybenzaldehyde (6.9 g, 0.06 mol), 1-methylpiperidin-
4-one (3.22 g, 0.03 mol), acetic acid (70 ml), and ethanolic HCl (30 ml) were heated at 
~70°C overnight. The solid was filtered and stirred with potassium carbonate solution 
(20%, 100 ml, w/v) for two hours. The solid was filtered and dried at 55-60 °C in a 
vacuum oven to give (3E,5E)-3,5-bis(4-hydroxybenzylidene)-1-methylpiperidin-4-one 
and recrystallized from isopropyl ether to give 1.12 g (yield 12%). M.p. 245-249 °C. 
[lit.58 m.p. 197-199 °C]. 1H NMR (DMSO-d6): δ 2.40 (s, 3H, NCH3), 3.65 (s, 4H, 2 x 
CH2NCH3), 6.73 (d, 4H, 2 x aryl H), 7.26 (d, 4H, 2 x aryl H), 7.47 (s, 2H, 2 x CH). 
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3.1.1.2.2 Synthesis of (3E,5E) 3,5-bis{4-[4-(2-diethylaminoethoxy)phenyl-
carbonyloxy]benzylidene}-1-methyl-4-piperidone (2b) 
 
 
Figure 3-18: Structure of compound 2b 
 
4-(2-(Diethylamino)ethoxy)benzoyl chloride hydrochloride was prepared by 
adding thionyl chloride (25 ml) to 4-(2-(diethylamino)ethoxy)benzoic acid hydrochloride 
(1g) and heated at ~70°C for 2-3 h. On cooling, solvent was evaporated to yield 4-(2-
(diethylamino)ethoxy)benzoyl chloride hydrochloride which was used without further 
purification.  
 
Triethylamine (2.18 g, 0.02 mol) in 1,2-dichloroethane (10 ml) was added 
dropwise to a stirred suspension of (3E,5E)-3,5-bis(4-hydroxybenzylidene)-1-
methylpiperidin-4-one58 (1 g, 0.003 mol) and 4-(2-(diethylamino)ethoxy)benzoyl 
chloride hydrochloride (2.4 g, 0.01 mol) in 1,2-dichloroethane (30 ml) at ~5 °C for a 
period of 30 min under nitrogen. The reaction mixture was stirred at room temperature 
overnight. The mixture was filtered and the solvent evaporated. The residue was stirred in 
potassium carbonate solution (70 ml, 7% w/v) for two hours. The solid obtained was 
filtered, dried in a vacuum oven at 50° C, and crystallized from ethyl acetate to yield the 
pure compound (1.6 g, yield 70%). M.p. 122-125 °C. Yield 70%. 1H NMR (CDCl3): δ 
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1.10 (d, 12H, 4 X CH3CH2N), 2.52 (s, 3H, CH3N), 2.65 (m, 8H, 4 x CH3CH2N), 2.93 (t, 
4H, 2 x OCH2CH2N), 3.81 (s, 4H, 2 x CH3NCH2), 4.15 (t, 4H, 2 x OCH2CH2N), 6.99 (t, 
4H, aryl H), 7.29 (d, 4H, aryl H), 7.48 (d, 4H, aryl H), 7.85 (s, 2H, 2 x CH), 8.16 (d, 4H, 
aryl H). 13C NMR (CDCl3): δ 186.812, 164.720, 163.438, 151.507, 135.576, 133.142, 
132.843, 132.378, 132.326, 131.646, 122.084, 121.440, 121.163, 114.465, 114.389, 
77.294, 77.040, 76.786, 67.050, 57.082, 51.578, 47.945, 45.924, 30.979, 11.884. MS m/z 
760.4 [M + H]. Found C, 72.02; H, 6.96; N, 5.33%. Anal. (C46H54N307.5) requires C, 
71.79; H, 7.02; N, 5.46%.  
 
3.1.1.2.3 Synthesis of (3E,5E) 3,5-bis{4-[4-(2-piperidin-1-ylethoxy)phenyl-
carbonyloxy]benzylidene}-1-methyl-4-piperidone (2c) 
 
 
Figure 3-19: Structure of compound 2c 
 
4-(2-(Piperidin-1-yl)ethoxy)benzoyl chloride hydrochloride was prepared by 
adding thionyl chloride (25 ml) to 4-(2-(piperidin-1-yl)ethoxy)benzoic acid hydrochloride 
and heated at ~70°C for 2-3 h. On cooling, the solvent was evaporated to yield 4-(2-
(piperidin-1-yl)ethoxy)benzoyl chloride hydrochloride which was used without further 
purification.  
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Triethylamine (0.8 g, 0.01 mol) in chloroform (10 ml) was added dropwise to a 
stirred suspension of (3E,5E)-3,5-bis(4-hydroxybenzylidene)-1-methylpiperidin-4-one58 
(1 g, 0.003 mol) and 4-(2-(piperidin-1-yl)ethoxy)benzoyl chloride hydrochloride (2.4 g, 
0.01 mol) in 1,2-dichloroethane (30 ml) at ~5 °C for a period of 30 min under nitrogen. 
The reaction mixture was stirred at room temperature overnight. The mixture was filtered 
and the solvent evaporated. The residue was stirred in potassium carbonate solution (70 
ml, 7% w/v) for two hours. The solid obtained was filtered, dried in a vacuum oven at 
50° C to yield the pure compound (580 mg, yield 25%). M.p. 135-137 °C. Yield 24 %. 1H 
NMR (CDCl3): δ 1.42 (s, 3H, CH3), 1.62 (m, 10H, piperidine protons), 2.52 (d, 10H, 
piperidine protons), 2.82 (t, 4H, 2 x CH2CH2N), 3.81 (s, 4H, 2 x CH2NCH3), 4.21 (t, 4H, 
OCH2CH2N), 7.11 (d, 4H, aryl H), 7.31 (s, 4H, aryl H), 7.43 (m, 4H, aryl H), 7.85 (s, 2H, 
2 x CH), 8.16 (d, 4H, aryl H). 13C NMR (CDCl3): δ 186.811, 164.708, 163.391, 151.500, 
135.569, 133.148, 132.848, 132.378, 131.644, 122.081, 121.476, 114.505, 77.292, 
77.038, 76.784, 66.421, 57.763, 57.082, 55.167, 45.923, 30.974, 25.977, 24.180, 1.044. 
MS m/z 784.6 [M + H]. Found C, 72.78; H, 7.00; N, 5.03%. Anal. (C48H54N3O7.5) 
requires C, 72.64; H, 6.8; N, 5.30%.  
 
3.1.1.2.4 Synthesis of (3E,5E) 3,5-bis(4-(4-(2-(4-morpholino)ethoxy)phenyl 
carbonyloxy)benzylidene)-1-methyl-4-piperidone (2d) 
 
Figure 3-20: Structure of compound 2d 
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4-(2-Morpholin-4-ylethoxy)benzoyl chloride hydrochloride was prepared by 
adding thionyl chloride (25 ml) to 4-(2-morpholin-4-ylethoxy)benzoic acid hydrochloride 
and heated at ~70°C  for 2-3 h. On cooling, solvent was evaporated to yield 4-(2-
morpholin-4-ylethoxy)benzoyl chloride hydrochloride which was used without further 
purification.  
 
Triethylamine (0.9 g, 0.01 mol) in 1,2-dichloroethane (10 ml) was added 
dropwise to a stirred suspension of (3E,5E)-3,5-bis(4-hydroxybenzylidene)-1-
methylpiperidin-4-one58 (0.6 g, 0.002 mol)  and 4-(2-morpholin-4-ylethoxy)benzoyl 
chloride hydrochloride (1.25 g, 0.004 mol) in 1,2-dichloroethane (30 ml) at ~5 °C for a 
period of 30 min under nitrogen. The reaction mixture was stirred at room temperature 
overnight. The mixture was filtered and the solvent evaporated. The residue was stirred in 
potassium carbonate solution (70 ml, 7% w/v) for two hours. The solid obtained was 
filtered, dried in a vacuum oven at 50° C, and crystallized from ethanol to yield the pure 
compound (0.93 g, yield 68%). M.p. 160-165 °C. Yield 68%. 1H NMR (CDCl3): δ 1.64 
(s, 4H, 2 x NCH2), 2.52 (d, 3H, CH3N), 2.63 (s, 8H, morpholinyl protons), 2.87 (t, 4H, 2 
x CH2NCH3), 3.77 (q, 8H, morpholinyl protons), 4.22 (t, 4H, 2 x CH2O), 7.02 (d, 4H, 
aryl H), 7.31 (s, 4H, aryl H), 7.48 (d, 4H, aryl H), 7.85 (s, 2H, 2 x CH), 8.17 (d, 4H, aryl 
H). 13C NMR (CDCl3): δ 186.789, 164.656, 163.198, 151.471, 135.567, 133.143, 
132.871, 132.413, 131.650, 122.069, 121.682, 111.476, 77.296, 77.043, 76.788, 66.931, 
66.165, 57.463, 57.072, 54.157, 45.916, 1.046. MS m/z 788.6 [M + H]. Found C, 66.34; 
H, 6.20; N, 5.00%. Anal. (C46H54N3O11.5) requires C, 66.27; H, 6.48; N, 5.04%.  
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3.2 Bioevaluations 
3.2.1 Materials and Methods 
3.2.1.1 Cytotoxic assays  
Series 1 and 2 compounds were evaluated against L1210, Molt 4/C8, CEM, and 
HeLa cells using a previously reported procedure.59 Different concentrations of the 
compounds were incubated with the appropriate cell line in RPMI 1640 medium at 37 ˚C 
for 72h (Molt 4/C8 and CEM) or 48h (HeLa and L1210). Cell numbers were determined 
using a Coulter counter. The IC50 value given is the concentration required to inhibit cell 
proliferation by 50%. Data are expressed as the mean ±SD from the dose–response 
curves of at least three independent experiments. Melphalan and curcumin were 
employed under the same conditions as positive controls. 
Compounds in series 1 and 2 were evaluated at a concentration of 5 or 1 µM 
against JURKAT, BJAB, Nalm-6, EL-4, BW5147, LNcAP, and DU145, RAJI B, Ramos, 
HUT-102, Molt-3, Sup-T1, HT-29, COLO 205, LAPC4, HCC70, and Hs27 cell lines. A 
solution of each compound in series 1 and 2 in DMSO-d6 was added to the cells grown in 
the appropriate (RPMI or DMEM) media, and incubated for 22 h at 37 ˚C. The average 
cytotoxicity of three independent experiments was obtained by observing the plasma 
membrane disruption using flow cytometry with propidium iodide.60  
Series 1 and 2 compounds were also evaluated against human oral non-malignant 
and neoplastic cell lines HGF, HPC, HPLF, HSC-2, HSC-3, HSC-4, and HL-60 
following a literature method except for the incubation time (48h). Various 
concentrations (maximum of 400 µM) of each compound as well as untreated cells were 
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added to cultured cells and incubated for 48h at 37 °C. The cytotoxic concentration 
(CC50) values were determined from dose-response curves and the figures represent the 
mean from duplicated experiments.61  
3.2.1.2 MDR-reversal assay  
Series 2 compounds were added to a transfected murine lymphoma 5178Y cells 
with the mdr-1 gene following a literature procedure62 and cultured in the presence of 
colchicine in order to maintain the expression of the MDR phenotype. Solutions of two 
concentrations (5 and 50 µg/mL) of the compounds in dimethylsulfoxide were added to 
mdr-1 transfected and the L5178 parenteral cells  at room temperature and incubated for 
10 min. Then, rhodamine 123 solution was added and the cells were incubated for a 
further 20 min at 37 °C. The fluorescence of the parental and mdr-1 treated and untreated 
cells was measured with a Becton-Dickinson FACScan flow cytometer. Verapamil was 
used as a positive control. Fluorescence activity ratio (FAR) for each compound were 
calculated from the following equation: 
 
Equation 3-1: The fluorescence activity ratio equation 
Verapamil was used as a positive control using an intermediate concentration  between 5 
and 50 µg/mL, namely 10 µg/mL.63  
 
FAR =
MDR treated / MDR control
parental treated / parental control
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CHAPTER 4 
4. Results and Discussion 
4.1 Results  
Series 1 and 2 were synthesized successfully. The elemental analyses (for carbon 
and hydrogen for all compounds, and nitrogen when present in the molecules) were 
within 0.4% of the calculated values. In series 2, the E stereochemistry was confirmed 
using 1H NMR spectroscopy. The auxiliary binders 1 were prepared by the sequence of 
reactions as illustrated in Scheme 4-1. The synthesis of 3 was previously reported.39 
Ethyl, methyl, and isopropyl esters 1a-c,e-g,i-l were prepared by reacting 2,3, or 4- 
substituted benzoic acids with thionyl chloride to afford the corresponding acid chlorides. 
Subsequent condensation was followed with ethyl, methyl, and isopropyl alcohols to 
afford the corresponding esters 1a-c,e-g,i-l. Compound 1d was prepared by different 
method. The acid chloride of compound 3 was prepared by the reaction of 3 with thionyl 
chloride, followed by a reaction with piperidine under cooling which afforded 1d. The 
alkaline catalyzed condensation of ethyl and methyl 4-hydroxy benzoate and isopentyl 
bromide under basic conditions afforded the ethyl and methyl esters 1h and 1m. The 
synthetic endeavor for series 1 is presented in Scheme 4-1. Series 2 was prepared by the 
condensation of 4-hydroxybenzaldehyde and N-methyl-4-piperidone under acidic 
conditions to afford 3,5-bis(4-hydroxybenzylidene)-1-methylpiperidin-4-one 2a. For 2b-
d, the reaction took place by adding the appropriate aroyl chlorides in series 1 to 3,5-
bis(4-hydroxybenzylidene)-1-methylpiperidin-4-one under basic conditions. This 
endeavor is indicated in Scheme 4-2.  
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Scheme 4-1: Synthetic endeavors of analogs 1a-m 
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Scheme 4-2: Synthetic endeavors of analogs 2a-d 
 
All of the compounds in series 1 and 2 were evaluated towards various human and 
murine transformed cells in order to determine their cytotoxic effects. As well, normal 
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cells were also involved in the biological evaluations to determine whether these 
compounds have greater toxicity to neoplasms than non-malignant cells. Melphalan and 
curcumin were used as the standard anticancer drugs in these assays.  
 
Specifically the following bioevaluations were undertaken. All of the compounds 
in series 1 and 2 were evaluated against murine L1210 lymphocytic leukemia cells and 
human Molt4/C8 and CEM T-lymphocytes as well as human HeLa cervix carcinoma 
cells. Cytotoxic potencies are expressed as IC50 values and the biodata are presented in 
Tables 4-1 and 4-2. The clogP values for the compounds in series 1 and 2 were obtained 
from a commercial software package and these results are indicated in the same tables as 
well. The IC50 values of previously reported compounds from this laboratory 4a-c and 
5a-d (Figure 4-1) are also indicated in the Table 4-2 for comparison purposes.39,64  
         
 
Figure 4-1: Structures of series 4 and 5 
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Table 4-1: Evaluation of series 1a-m and analog 3 against Molt4/C8, CEM, L1210, and 
HeLa cancer cells59       
IC50  (µM)a  
Compd L1210 Molt4/C8 CEM HeLa clogP b 
1a 193 ± 49 > 500 225 ± 49 246 ± 64 3.97 
1b 280 ± 60 > 500 276 ± 51 278 ± 60 3.44 
1c 102 ± 19 205 ± 2 192 ± 31 147 ± 45 4.28 
1d 365 ± 166 > 500 355 ± 123 354 ± 56 3.18 
1e 232 ± 33 338 ± 35 229 ± 28 ≥ 500 2.91 
1f 170 ± 3 220 ± 2 173 ± 10 206 ± 2 4.15 
1g 358 ± 30 441 ± 83 286 ± 1 222 ± 19 2.93 
1h 105 ± 43 51.8 ± 1.6 69.4 ± 17.3 154 ± 67 5.86 
1i 129 ± 18 224 ± 5 174 ± 21 232 ± 12 3.26 
1j 340 ± 57 > 500 248 ± 25 308 ± 182 3.73 
1k 216 ± 0 176 ± 15 180 ± 20 187 ± 16 3.97 
1l 244 ± 30 400 ± 47 232 ± 18 294 ± 101 2.91 
1m 208 ± 8 220 ± 3 191 ± 21 292 ± 90 4.27 
3 >500 >500 >500 >500 0.91 
 
a The IC50 value is the concentration of a compound required to inhibit the growth of the 
cells by 50%.  
b The clogP values were obtained from ChemDraw software. 
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Table 4-2: Evaluation of series 2, 4, and 5 against Molt4/C8, CEM, L1210, and HeLa 
cancer cells59        
IC50  (µM)a  
Compd L1210 Molt4/C8 CEM HeLa clogPb 
2a 55.7 ± 20.2 18.9 ± 7.8 19.2 ± 12.6 18.9 ± 7.2 2.92 
2b 10.5 ± 1.0 43.6 ± 0.6 27.8 ± 17.8 20.2 ±11.7 9.75 
2c 6.05 ± 1.94 22.3 ± 13.8 16.5 ± 9.3 8.21 ±0.85 10.22 
2d 7.82 ± 4.03 12.0 ± 0.6 30.8 ± 17.3 10.5 ± 3.6 7.80 
4a 8.77 ± 0.28  1.98 ± 0.27 3.32 ± 2.30 N/Ac 3.39 
4b 305 ± 10 277 ± 6 233 ± 27 N/Ac 4.36 
4c 281 ± 15 230 ± 1 172 ± 6 N/Ac 3.13 
5ad 10.2 ± 0.8 0.58 ± 0.09 1.24 ± 0.57 N/Ac 5.18 
5bd 8.23 ± 0.43 1.28 ± 0.15 1.65 ± 0.15 N/Ac 6.24 
5cd 8.40 ± 0.22 1.48 ± 0.12 1.16 ± 0.64 N/Ac 6.41 
5dd 222 ± 13 8.42 ± 0.16 6.84 ± 0.09 N/Ac 5.20 
Curcumin 15.1 ± 1.6 6.46 ± 1.41 8.16 ± 1.66 21.2 ±16.1 2.25 
Melphalan 4.85 ± 0.87 2.81 ± 0.33 1.44 ± 0.20 1.70 ±0.44 - 0.207 
 
a The IC50 value is the concentration of a compound required to inhibit the growth of the 
cells by 50%.  
b The clogP values were obtained from ChemDraw software. 
c N/A means that the result is not available. 
d The data for the IC50 values were taken from reference 46 and are reproduced by 
permission of the copyright owner.  
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Some of compounds in series 1 were screened against human Jurkat, EL-4, BW5147, 
BJAB, Nalm-6 lymphocytic leukemia, LNcAP and DU145 prostate carcinoma cells at a 
concentration of 5 µM. The biological activity was expressed as the growth inhibition 
percentages. These data are presented in Table 4-3.!
!68!
T
able 4-3: Evaluation of 1e-g,i-l and 3 against various cancer cells 60 
%
 G
row
th Inhibition
  
C
om
pd  
µM
 
JU
R
K
A
T 
B
JA
B
 
N
alm
-6 
EL-4 
B
W
5147 
LN
cA
P 
D
U
145 
1e 
5 
0.4 ± 0.7 
3.9 ± 6.1 
1.1 ± 1.0 
1.7 ± 3.0 
0.0 ± 0.0 
1.4 ± 2.4 
2.3 ± 2.0 
1f 
5 
0.3 ± 0.3 
0.4 ± 0.7 
1.9 ± 1.7 
0.3 ± 0.4 
0.5 ± 0.5 
1.3 ± 2.2 
6.6 ± 11.4 
1g 
5 
20.3 ± 34.6 
0.7 ± 1.1 
1.3 ± 1.1 
1.5 ± 1.0 
1.4 ± 1.1 
2.1 ± 1.8 
16.4 ± 24.1 
1i 
5 
0.4 ± 0.1 
6.5 ± 6.1 
1.2 ± 0.6 
1.7 ± 2.9 
0.2 ± 0.2 
4.2 ± 4.0 
5.2 ± 3.8 
1j 
5 
0.5 ± 0.8 
3.6 ± 3.6 
3.1 ± 1.7 
2.9 ± 2.2 
0.6 ± 0.6 
0.5 ± 0.5 
32.3 ± 33.1 !
!
1k 
5 
1.5 ± 2.5 
1.2 ± 0.2 
0.1 ± 0.1 
2.8 ± 2.2 
0.3 ± 0.3 
1.4 ± 1.4 
0.0 ± 0.0 
1l 
5 
0.1 ± 0.2 
7.6 ± 3.0 
0.0 ± 0.0 
0.4 ± 0.6 
0.6 ± 0.7 
0.0 ± 0.0 
1.8 ± 3.2 
3 
5 
0.1 ± 0.1 
1.5 ± 2.1 
0.0 ± 0.0 
0.5 ± 0.5 
0.0 ± 0.0 
1.3 ± 1.9 
0.0 ± 0.0 
M
elphalan 
5 
0.8 ± 0.5 
5.1 ± 6.2 
21.4 ± 15.8 
21.1 ± 5.1 
0.8 ± 0.7 
0.0 ± 0.0 
0.4 ± 0.7 
C
urcum
in 
5 
1.6 ± 1.1 
12.8 ± 8.0 
5.0 ± 2.6 
21.3 ± 1.4 
0.0 ± 0.0 
0.6 ± 1.1 
4.5 ± 7.4 
!!
!
!!
!
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Series 2 compounds were screened against human Hs27 fibroblast, Jurkat and 
Nalm-6 lymphocytic leukemia cells at a concentration of 1 µM. These data are presented 
in Table 4-4. The activity was expressed as the growth inhibition percentages.  
 
Table 4-4: Evaluation of 2a-d against Jurkat, Nalm-6, and Hs27 cell lines60 
% Growth Inhibitiona 
Compd. 
Jurkat SIb Nalm-6 SIb Hs27 
2a 19.8±26.3 49.5 28.0±7.0 70.0 0.4±0.7 
2b 65.3±7.0 >65.3 65.1±24.1 >65.1 0.0±0.0 
2c 13.2±15.7 >13.2 36.3±28.0 >36.3 0.0±0.0 
2d 6.7±11.7 0.40 25.6±23.4 1.54 16.6±17.0 
 
a The figures indicate the percentage inhibition of growth at a concentration of 1 µM for 
each compound.  
b The letters SI indicate the selectivity index which is the ratio of the percentage 
inhibition of Jurkat or Nalm-6 lymphomas to the Hs27 cells. 
 
 
Compound 2b was extensively evaluated at concentration of 1 µM towards 
various human neoplasms namely murine EL4 T-lymphoma, human CEM T, RAJI B, 
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BJAB B, RAMOS B, SUPT-1 T-lymphoma cells, human HUT-102 T-, MOLT-3 T- cells 
leukemia, human HT-29 and COLO 205 colon cancer cells, human LAPC4 prostate 
cancer cells, and HCC70 breast cancer cells. The cytotoxic potencies of the compounds 
were expressed as the growth inhibition percentages, and indicated in Table 4-5. 
 
Table 4-5: Evaluation of 2b against twelve cancer cell lines at 1 µM60 
Cell Line % Growth Inhibitiona 
RAJI B 69.5 ± 10.6 
BJAB B 13.2 ± 14.0 
Ramos 89.3 ± 1.3 
HUT-102 2.2 ± 2.9 
Molt-3 15.3 ± 21.6 
Sup-T1 44.5 ± 42. 6 
EL-4 57.7 ± 16.3 
HT-29 23.0 ± 20.4 
COLO 205 11.7 ± 20.2 
LAPC4 18.9 ± 19.3 
HCC70 10.0 ± 14.3 
CEM T 82.2 ± 18.3 
 
a The figures indicate the percentage inhibition of growth at concentration of 1 µM for 
each compound.  
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Compounds in series 1 and 2 were also evaluated in another assay towards human HL-60 
promyelocytic leukemic cells and human oral squamous cell carcinomas (HSC-2, HSC-3, 
and HSC-4). In addition, these compounds were evaluated against human HGF, HPC, 
HPLF non-malignant cells in order to examine the possible selectivity of the compounds 
towards neoplasms. The data expressed as CC50 values are presented in Table 4-6. !
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1a 
229±28 
>1.70 
>400 
<0.97 
308±61 
>1.26 
113±21 
>3.44 
>400 
366±47 
>400 
>388.67 
1b 
380±12 
>1.05 
>400 
<1.00 
351±50 
>1.14 
150±31 
>2.67 
>400 
>400 
>400 
>400.00 
1c 
143±8.4 
2.03 
268±21 
1.08 
191±16 
1.52 
42±16 
6.91 
324±3.0 
202±8.7 
345±3.5 
290.33 
1d 
>400 
<1.00 
>400 
<1.00 
>400 
<1.00 
230±21 
>1.74 
>400 
>400 
>400 
>400.00 
1e 
574±52 
0.92 
>800 
<0.66 
>800 
<0.66 
>800 
<0.66 
694±25 
332±14 
563±7 
529.67 
1f 
167±20 
1.33 
283±8 
0.78 
19±5 
11.68 
554±28 
0.40 
286±3 
139±18 
241±6 
222.00 
1g 
347±16 
1.16 
690±145 
0.58 
502±218 
0.80 
664±31 
0.61 
549±49 
315±146 
345±18 
403.00 
1h 
75±2.0 
2.96 
161±19 
1.38 
139±7.0 
1.60 
57±11 
3.90 
285±11 
127±5.3 
255±21 
222.33 
1i 
327±34 
>1.70 
342±9 
>1.62 
701±62 
<0.79 
>800 
<0.69 
>800 
539±28 
324±19 
>554.33 
1j 
370±120 
>2.16 
495±31 
>1.62 
29±19 
>27.59 
390±21 
>2.05 
800> 
800> 
>800 
>800.00 
1k 
410±26 
0.98 
287±20 
1.40 
334±18 
1.20 
705±16 
0.57 
519±13 
253±22 
432±54 
401.33 
1l 
456±56 
0.97 
707±32 
0.63 
506±233 
0.87 
>800 
<0.55 
658±58 
282±39 
387±11 
442.33 
1m
 
54±6.4 
3.98 
153±6.0 
1.41 
134±17 
1.60 
66±30 
3.26 
270±11 
142±2.5 
233±28 
215.00 
2a 
3.0±1.3 
>95.67 
51±25 
>5.63 
6.6±0.9 
>43.48 
23±4.2 
>12.48 
384±23 
77±11 
>400 
>287.00 
2b 
31±4.6 
4.98 
50±5.5 
3.09 
63±6.0 
2.45 
32±11 
4.82 
123±25 
240±17 
100±17 
154.33 
2c 
9.0±0.8 
9.11 
19±0.6 
4.32 
17±1.3 
4.82 
11±3.1 
7.45 
51±6.7 
159±19 
36±2.1 
82.00 
2d 
9.8±3.8 
>30.44 
31±5.9 
>9.62 
26±3.2 
>11.47 
15±2.7 
>19.89 
>400 
95±15 
>400 
>298.33 
M
elphalan 
13.1±2.5 
15.27 
49±15 
4.08 
78±19 
2.56 
11±5.1 
18.18 
255±75 
78±13 
267±153 
200.00 
C
urcum
in 
10±0.81 
4.53 
16±2.7 
2.83 
14±3.2 
3.24 
7.8±0.58 
5.81 
70±12 
34±6.8 
32±6.4 
45.33 
a The C
C
50  values are the concentrations of the com
pounds required to kill 50%
 of the cells. 
b SI refers to the selectivity index, and represents the quotients of the average C
C
50  value of the com
pound tow
ards norm
al cells and the C
C
50  figure generated for each 
neoplastic cell line. 
                       c These figures are the average C
C
50  values of the com
pounds tow
ards H
G
F, H
PC
 and H
PLF cell lines. 
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The target compounds 2a-d were also screened in a MDR reversal assay at 
concentrations of 5 and 50 µg/mL in order to measure their MDR-revertant activity 
towards P-gp MDR cells. These data are presented in Table 4-7. 
 
Table 4-7: Effect of 2a–d on multidrug resistance in murine L5178 lymphoma cells62 
Compd µg/ml FARa 
5 1.57 
2a 
50 1.37 
5 3.53 
2b 
50 118.15 
5 1.91 
2c 
50 43.19 
5 3.41 
2d 
50 12.70 
Verapamil 10 15.68 
 
a The fluorescence activity ratio (FAR) values are the ratios of the fluorescence intensities 
of rhodamine 123 in treated and untreated murine L5178 lymphoma cells transfected with 
the human MDR-1 gene. 
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4.2 Discussion  
The primary interest in this laboratory is the synthesis and bioevaluations of 
conjugated arylidene ketones designed as antineoplastic agents. These compounds have 
shown greater preferential affinity for thiols rather than amino and hydroxy groups.65 
Since thiols are absent in the nucleic acids, genotoxicity may be avoided by using these 
unsaturated ketones in comparison to contemporary anticancer drugs which generally 
interact with nucleic acids.66  Initially, compounds which contain one 3-aryl-2-propenoyl 
group (ARCH=CHCO) were prepared. However, various studies revealed that the 
inclusion of a dienone moiety into candidate cytotoxins led to the capacity for a 
sequential attack on the olefinic carbon atoms which can be more detrimental to 
malignant cells than normal tissues. 67,68 Therefore, the 1,5-diaryl-3-oxo-1,4-pentadienyl 
pharmacophore (ARCH=CHCOCH=CHAR) has been included in the design of a number 
of antineoplastic agents.69  
 
The rationale for preparing the auxiliary binders and the information obtained 
from these biodata in regards to producing directions for development of the project in 
the future is now presented. The auxiliary binders 1a-m were designed to be incorporated 
into the target compounds. In order to examine the viability of the hypothesis postulated 
earlier, three esters 2b-d were synthesized and evaluated for their cytotoxic potencies. 
The target compounds 2b-d are esters and consequently most of the auxiliary binders are 
prepared as such. The biological evaluation of 1a-d should point out whether the rates of 
hydrolysis or the differences in lipophilicity influence the cytotoxic potencies. In 
addition, the significance of the basic centre in 1a should be addressed; hence, its 
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bioactivity could be compared with that of 1e-g. The basic centre might not be required 
for the cytotoxic activity, and therefore the synthesis and bioevaluations of 1h and 1m 
was proposed. Another feature of these compounds is the spacer group between the aryl 
ring and the basic centre. Hence, comparing the IC50 values of 1i and 1e should enable an 
estimate of the contribution of the spacer group to cytotoxic potencies. Together with this 
consideration, the relative positions of the ethyl ester group and the diethylaminoethoxy 
and dimethylaminoethoxy are of importance. Thus, a small series of analogs 1j,k and 1l 
were prepared to compare their bioactivities with 1a and 1e.  
 
All of the compounds in series 1 and 2 were evaluated against murine L1210 
lymphocytic leukemia cells and human Molt 4/C8 and CEM T-lymphocytes as well as 
human cervical cancer HeLa cells. These biodata are presented in Tables 4-1 and 4-2. 
The L1210 screen was employed because of the sensitivity of these cells towards a 
number of anticancer drugs.70 The Molt 4/C8, CEM, and HeLa assays were undertaken in 
order to examine whether the compounds have any effects on transformed and malignant 
human cells. These biological data may identify lead compounds. Comparisons between 
the IC50 values of various compounds were undertaken in order to seek any correlations 
between the structures of series 1 and 2 and their cytotoxic potencies. The standard 
deviations were taken into account in making these comparisons.  
 
The IC50 values of series 1 against the four cell lines are presented in Table 4-1. 
Eight comparisons (I-VIII) between the IC50 values of various compounds were made in 
an effort to discern any structure-activity relationships (SAR). When comparing the 
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cytotoxic potencies of more than two compounds, the compound(s) with the lowest IC50 
values are assigned as the potent compound(s). These comparisons are presented in Table 
4-8.  
 
Table 4-8: Comparisons between the cytotoxic potencies of some of the compounds in 
series 1a-m and 3 
Cell Line 
No. Comparison 
L1210 Molt 4/C8 CEM HeLa 
I 1a, 1e, 1f, 1g 1a, 1e, 1f > 1g 1f > 1a, 1e, 1g 1a, 1e, 1f > 1g 1a, 1f, 1g > 1e 
II 1a, 3 1a > 3 1a = 3 1a > 3 1a > 3 
III 1a-d 1c > 1a, 1b, 1d 1c > 1a, 1b, 1d 1a = 1b, 1c, 1d 1a = 1b, 1c, 1d 
IV 1e, 1i 1i >1e 1i >1e 1i >1e 1i >1e 
V 1a, 1j, 1k 1a, 1k > 1j 1k > 1a, 1j 1a = 1k, 1j 1a = 1k, 1j 
VI 1k, 1l 1k = 1l 1k > 1l 1k > 1l 1k = 1l 
VII 1e, 1h 1h > 1e 1h > 1e 1h > 1e 1h > 1e 
VIII 1h, 1m 1h > 1m 1h > 1m 1h > 1m 1h = 1m 
 
(I) Comparing the amino group in the 4-alkylaminoethoxy substituents revealed 
that the relative potencies are 1f > 1a > 1e > 1g. This result may be due to the 
lipophilicity of 1f and 1a which have clogP values of approximately 4 whereas in the 
case of 1e and 1d, the clogP figures are approximately 3. (II) The reduction of the 
polarity of the carboxylic acid group in 3 by its conversion into the corresponding ethyl 
ester 1a led to increases in the cytotoxic potency generally and this result could be due to 
! 77!
increases in both lipophilicity and membrane permeability. (III) Comparing the cytotoxic 
potencies of the potential prodrugs of 3 namely 1a-d revealed that the isopropyl analog 
1c is more cytotoxic than the other esters 1a, 1b, 1d. The isopropyl ester has the highest 
lipophilicity which may contribute to the increased cytotoxicity. (IV) The ester 1i, which 
has the trimethylene spacer between the nitrogen and oxygen atoms, is more potent than 
the dimethylene spacer analog 1e. Therefore, the distance between the nitrogen and 
oxygen atoms in the alkylaminoalkoxy substituents, which are able to form hydrogen 
bonds at the receptor, should be investigated in order to obtain more potent auxiliary 
binders. (V) In 1j, 1k, and 1a, the 2-diethylaminoethoxy substituents are placed in the 
ortho-, meta-, and para- positions of the aryl ring, respectively. The order of potency is 
1k > 1a > 1j which indicates that the ortho structural isomer is the least potent, and the 
meta- structural isomer has the maximum potency. (VI) Comparing the dialkylamino 
group in the compounds containing meta- 2-alkylaminoethoxy substituents 1k and 1l 
revealed that the diethylamino analog 1k is more potent than the dimethylamino analog 
1l. This result may be due to the higher lipophilicity of 1k which has a clogP value of 
approximately 4. (VII) The isosteric replacement of the basic centre in 1e by a methine 
group led to 1h which has increased cytotoxic potency compared to 1e. In fact, 1h 
displayed the most potent cytotoxicity in series 1 towards both T-lymphocytes. That 
could be due to its having the highest clogP value among the compounds in series 1.  
(VIII) Comparing the ethyl 1h and methyl 1m esters revealed that the ethyl ester is more 
potent which might be due to the reduced clogP value in 1m.  
 !
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In conclusion, these biodata could be utilized in designing modified molecules in 
the future in order to obtain more cytotoxic molecules, e.g., by considering the optimal 
aryl substituents, as well as the optimal ester groups. Specifically 1h is the most potent 
molecule having an average IC50 value of 61 µM towards both T-lymphocytes. Moreover, 
the lipophilicity of the molecules based on the clogP values appears to display a 
significant role in the relative potencies of the compounds. 
 
The target compounds 2b-d were prepared as hybrids (Figure 4-2) between a 
candidate cytotoxin 2a and the auxiliary binders 1a, f, and 1g. The cytotoxicity of 2a in 
these bioassays has not been reported previously and therefore its potency needed to be 
determined. The bioevaluations of 2b-d was planned in order that the following 
comparisons of potencies between different compounds could be undertaken. First, the 
IC50 values of 2b-d can be compared with the analog which has no substituents in the 
arylidene aryl rings. In other words, does the incorporation of the auxiliary binder group 
onto these aryl rings decrease the IC50 values? Second, since 2b-d are esters, the 
possibility exist that these compounds will hydrolyze to 2a and various aromatic acids. 
Hence, comparisons between the potencies of 2b-d with 2a was planned. Third, the 
amino groups in 2b-d have different hydrophobic and electronic properties which may be 
reflected in changes in their cytotoxic potencies.  
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Figure 4-2: General structures of the compounds 2a-d 
 
Comparisons were also made between the IC50 values of the target compounds 
2b-d and series 4 in an effort to discern the effect of the auxiliary binders on cytotoxic 
potencies. Both series 2 and 4 share a structural similarity with the non-enolic form of 
curcumin which possesses two 3-aryl-2-propenoyl groups (ARCH=CHCO-). Hence, the 
cytotoxic potencies of these compounds were compared to curcumin. In addition, the 
potencies of the compounds were compared to melphalan which is an alkylating agent 
used in cancer chemotherapy. The IC50 values of series 2 against four cell lines are 
presented in Table 4-2. 
 
Compound 2a has IC50 values below 20 µM against both T-lymphocytes as well 
as the HeLa bioassay, and is equipotent with curcumin towards CEM and HeLa cells. The 
biodata for compounds 2b-d revealed that IC50 values were below 20 µM for 2b in the 
L1210 assay, 2c in the L1210, CEM, and HeLa screens, and 2d in the L1210, Molt 4/C8, 
and HeLa assays. Comparing the three analogs 2b-d, the IC50 figures reveal that 2c and 
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2d are generally more potent than 2b. The three analogs 2b-d also displayed greater 
cytotoxic potencies than curcumin in some assays namely 2b in the L1210 assay, 2c in 
L1210 and the HeLa screens, and 2d in the L1210 assay. Equipotency with curcumin was 
observed for 2b in the HeLa screens, 2c in the CEM and HeLa screens, and 2d in HeLa 
assay. Moreover, comparing the IC50 values of 2a-d with melphalan revealed that 2c and 
2d were equipotent with this reference compound against L1210 cells.  
 
The investigation was undertaken to examine whether the attachment of the 4-(2-
aminoethoxy)phenylcarbonyloxy group to the aryl rings of 4a, as well as, the substitution 
of methyl group in 4b by the 4-(2-aminoethoxy)phenylcarbonyloxy substituent and the 
substitution of methyl group in 4c by the 4-(2-aminoethoxy)phenylcarbonyl substituent 
will increase or decrease the cytotoxic potency. The biodata are presented in Table 4-2, 
and reveal that in relative to 4a, the incorporating of the auxiliary binder in 2c increased 
the cytotoxic potencies in the L1210 assay, but not in T-lymphocytes assays. In relation 
to 4b, the incorporation of the 4-(2-aminoethoxy)phenylcarbonyloxy group led to a 
significant increase the potent cytotoxicity in all the three assays in general. In 
comparison with 4c, the incorporating of the auxiliary binders 2b, 2c, and 2d increased 
the cytotoxic potencies in the L1210 and the T-lymphocytes assays (Table 4-9).     !
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Table 4-9: Comparison of the cytotoxic potencies of 4a-c and the hybrid molecules 2b-d 
IC50 Ratio a 
L1210 Molt 4/C8 CEM Compd 
4a 4b 4c 4a 4b 4c 4a 4b 4c 
2b 0.84 29.1 26.8 0.05 6.4 5.28 0.12 8.4 6.19 
2c 1.45 50.4 46.5 0.09 12.4 10.3 0.20 14.12 10.42 
2d 1.12 39.0 35.9 0.17 23.1 19.2 0.11 7.57 5.6 
 
a The figures of the ratios of the IC50 values of 4a, 4b, and 4c divided by the IC50 values 
for 2b-d. 
 
A further biological evaluation of the representative auxiliary binders and the 
target compounds was undertaken in order to assess the extent of their cytotoxic 
potencies. Non-adherent malignant cells are capable of invading other organs after 
metastasis has occurred. Compounds with growth-inhibitory properties towards non-
adherent cells may therefore have the ability to prevent metastasis. The non-adherent 
cells are Jurkat, BJAB, Nalm-6, EL-4, CEM, Sup-T1, Ramos, and BW5147 cancer cells, 
Hs27 non-malignant cells, while the adherent cancer cells are LNcAP, DU145, RAJI B, 
HUT-102, Molt-3, HT-29,COLO 205, LAPC4, and HCC70. The auxiliary binders 1e-g, 
i-l and 3 were screened against non-adherent and adherent malignant cells namely human 
LNcAP, DU145 prostate malignant cells, human Jurkat and BW5147 T-cell lymphomas, 
murine EL-4 T-cell lymphoma, human BJAB and Nalm-6 B-cell lymphomas (Table 4-3). 
Series 2 were evaluated also against malignant non-adherent cells namely Jurkat T-
! 82!
lymphoma and Nalm-6 pre-B-lymphoma. Moreover, the non-malignant human Hs-27 
fibroblast cell line was employed to examine whether the compounds have greater 
potency towards neoplasms than non-malignant cells. One candidate 2b was broadly 
screened in twelve assays including lymphoma, leukemia, colon, prostate, and breast 
cancer cells. These cells are human RAJI, BJAB, and Ramos B-lymphomas, human Sup-
T1, CEM, and murine EL-4 T-lymphomas, human HUT-102 and Molt-3 T-cell leukemia 
cells, HT-29 and COLO 205 colon cancer cells, LAPC4 prostate cancer cells, and HCC70 
breast cancer cells. These biological data are presented in Tables 4-3, 4-4, and 4-5, 
respectively.  
 
A comparison between the percentages of growth inhibition of various 
compounds was undertaken at a concentration of 5 µM in order to seek any correlations 
between the structures of series 1 and their cytotoxic potencies. The standard deviations 
were taken into account in making these comparisons. However, it can be concluded that 
the percentages of growth inhibition of the compounds were below 10% in all assays, 
except for 1g towards Jurkat and DU145 cells and 1j against DU145 cells. 
 
The growth inhibition of compounds 2a-d against the three cell lines Jurkat, 
Nalm-6, and Hs-27 are presented in Table 4-4. A comparison between the percentages of 
growth inhibition of various compounds was made in an effort to discern any structure 
activity relationships (SAR). These biological data revealed that 2b is the most potent 
compound in series 2 and 2b is a lead compound. Compound 2b was the most potent in 
Jurkat assay, having a growth inhibition more than 50%. On the other hand, 2a, 2c, and 
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2d were equipotent towards Jurkat cells. In addition, 2b inhibited the growth of Nalm-6 
cells in excess of 50%. The biodata also reveals that both 2a-c are selective towards the 
malignant cells. The analog 2a, as well as the hybrid molecule 2d displayed toxicity 
towards non-malignant cells Hs-27 as they inhibited these cells growth by 0.4% and 
16.6% respectively.  
 
 Clearly, 2b is a lead compound; hence, additional screening was undertaken using 
twelve cancer cell lines at the concentration of 1 µM in order to examine its sensitivity 
towards various non-adherent lymphoma, leukemia, prostate, breast, and colon cancers 
(Table 4-5). The candidate 2b exhibited greatest potency towards RAMOS, RAJI, and 
EL4 cancer cell lines in which the percentages of growth inhibition are approximately 
above 90%, 70%, and 60% respectively. Hence, the IC50 values of 2b towards these three 
cell lines are in the sub-micromolar range, indicating that 2b is a lead molecule for 
further development.  
 
A further cytotoxicity study was undertaken in order to investigate whether the 
compounds are not only cytotoxic to neoplasms but have greater lethality to malignant 
cell lines. All of the compounds in series 1 and 2 were evaluated against four human 
neoplastic cell lines namely HL-60 promyelocytic leukemic cells as well as HSC-2, HSC-
3 and HSC-4 oral squamous cell carcinomas. In addition, they were screened against 
three human normal cells namely HGF gingival fibroblasts, HPC pulp cells and HPLF 
periodontal ligament fibroblasts. These biodata are presented in Table 4-6.  !
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The biodata of series 1 presented in Table 4-6 indicate that most of the 
compounds displayed cytotoxicity towards neoplasms at CC50 values higher than 100 
µM. However, some of the series 1 compounds displayed cytotoxic potency towards 
leukemia and specific squamous cells at CC50 values between 19-75 µM. The potencies in 
µM are given as follow: 1c 42 (HL-60), 1f 19 (HSC-4), 1h 57 and 75 (HL-60 and HSC-2 
respectively), 1j 29 (HSC-4), and 1m 54 and 66 (HSC-2 and HL-60) respectively. 
 
The biodata presented also reveal that 2a-d CC50 average values against the four 
cell lines are 20.9, 44.0, 14.0, and 20.5 µM respectively. The order of potencies are 
therefore 2c > 2a,d > 2b. Comparison of the CC50 values of 2a-d and melphalan in the 
three squamous cells carcinomas as well as leukemic cells reveal that 2a (3 and 6.6 µM), 
2c (9 and 17 µM), and 2d (9.8 and 26 µM) in HSC-2 and HSC-4 assays are more potent 
than melphalan. In addition, compound 2c displayed more potency (19 µM) than 
melphalan in the HSC-3 assay, whereas 2b is equipotent in the HSC-4 assay (63 µM). 
Significantly, 11 fold more potency than melphalan in the HSC-2 and HSC-4 assays (63 
µM) respectively, while 2c possess 1.5 and 4.6 folds more potency in the same assays, 
respectively.  
 
In order to address the compounds’ selective toxicity to neoplasms than normal 
cells, selectivity index (SI) figures were calculated for 1a-m and 2a-d. Under clinical 
conditions, the tumor cells are surrounded by a number of different types of normal cells 
and in order to stimulate the in vivo situations, the average CC50 value of the compounds 
towards the three normal cell lines was divided by the CC50 figure generated using each 
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neoplastic cell line. These data are presented in Table 4-6. 54% of the auxiliary binders 1 
have SI figures of greater than 1, while 46% have SI figures of lower than 1. All of the 
compounds in series 2 have SI average of greater than 1 which indicates that their 
toxicity towards normal cells are lower than to the neoplasms. These average figures are 
2a (36.8), 2b (2.18), 2c (2.69), and 2d (16.34), and it indicates that all of series 2 
compounds are more selective than the reference compounds melphalan and curcumin; in 
addition, 2a and 2d displayed greater selectivity than 2b and 2c.  
 
Multidrug resistance development is one of the main problems in cancer 
chemotherapy. Compounds that revert MDR may also exhibit antineoplastic activity, or if 
not, they can be co-administered with anticancer drug(s). MDR-revertants in both cases 
help in reducing the dose given and consequently potential toxicity is reduced. In order to 
determine whether a compound possesses MDR-reversal activity, murine L-5178 
lymphoma cells are transfected with the human MDR-1 gene.71 Measuring the 
fluorescence intensities in the rhodamine 123 treated and untreated transfected and 
parental cells enables the calculation of the fluorescence activity ratio (FAR) values. The 
FAR ratios indicate the magnitude of the MDR-reversal properties of the compounds; if 
they are above the value of 1 this means the molecule possess reversal activity. All of the 
compounds were assessed using concentrations of 5 and 50 µg/mL and the data are 
presented in Table 4-7. It was reported previously from this laboratory that 3,5-bis-
benzylidene-4-piperidones lack the MDR properties, while the N-acyl analogs 5 have 
high FAR values at a concentration of 4 µg/mL.40 Series 5, which has a 4-(2-
aminoethoxy)phenylcarbonyl group attached to the piperidyl nitrogen atom, exhibited 
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substantial MDR-revertant activities. Hence, the placement of the 4-(2-
aminoethoxy)phenylcarbonyloxy group to the arylidene aryl ring of 4a may produce 
MDR-revertant activity. Series 2a-d were screened in this assay using concentrations 5 
and 50 µg/mL and these biodata are presented in Table 4-7. In the higher concentration, 
the FAR values are 1.37, 118, 43.2, and 12.7, respectively.  It is clear that the hybrid 
molecules possess greater MDR-revertant activity than the hydroxy analog 2a. 
Significantly, 2b is the most potent compound and thus is considered a lead molecule. 
Although the potency of 2c is 2.7 fold lower than that of the lead molecule, its activity is 
still encouraging. At the low concentration of 5 µg/mL, the FAR values of 2a, 2b, 2c, and 
2d are 1.57, 3.53, 1.91, and 3.41 respectively. In comparison to the highest potencies of 
both 2a-d at the high concentration of 50 µg/mL and to series 5 at 4 µg/mL, they are in 
general, less potent MDR-revertants. Due to the solubility issues, verapamil was used as a 
positive control at concentration of 10 µg/mL and its FAR value is 15.68. !
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CHAPTER 5 
5. Conclusions 
 The aim of this project was the development of novel curcumin analogs 
containing the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore through the 
incorporation of auxiliary binders. These compounds are multi-targeted compounds, that 
is they could bind at the auxiliary binding site in addition to the interaction of the 1,5-
diaryl-3-oxo-1,4-pentadienyl group at the primary binding site. Cytotoxicity activity is 
taking place inter alia through thiol alkylation, which results in depleting GSH levels in 
tumor cells. Auxiliary binders might strengthen binding to the receptor only, or they 
might exhibit cytotoxic potency as well. If auxiliary binders display cytotoxic effects, 
they would be acting at sites far from the primary binding site. Three target compounds 
2b-d and the auxiliary binders 1a-m were synthesized using, on most occasions, various 
condensation reactions (pages 61-63), followed by their biological evaluation in vitro in 
order to examine the cytotoxic activity59-61 as well as the MDR62 properties of the 
candidate cytotoxins. In general some of the auxiliary binders and target compounds 
displayed encouraging cytotoxic potencies towards various human and animal malignant 
cell lines. As well, remarkable results were obtained in the MDR-reversal assay. The 
biological evaluation of the auxiliary binders 1a, 1f, and 1g towards four cancer cells 
L1210, Molt4/C8, CEM, and HeLa revealed that they lack significant cytotoxic potency 
(IC50 > 100 µM). For the other auxiliary binders in series 1, very low potencies were 
displayed (IC50 > 100 µM), except for one compound 1h towards both T-lymphocytes 
(IC50=61 µM). The attachment of 1a, 1f, and 1g to 2a led to the significant increased 
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potency of 2b-d in the same assay (IC50 = 13.3-25.5 µM). These data are presented in 
Tables 4-1 and 4-2, pages 65,66.   
 
Figure I: Chemical structures of 1a, 1f, and 1g 
 
 
Figure II: Chemical structures of 2a-d 
 
 To investigate the anti-metastasis activity of the target compounds 2b-d as well 
as the auxiliary binders 1, various adherent and non-adherent cancer cells (page 81) were 
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used and the percentage of growth inhibition was obtained60. The target compounds 2b-d 
showed favorable cytotoxic potencies in which the inhibition of tumor growth took place 
at micromolar and sub-micromolar concentrations. The incorporation of the auxiliary 
binders 1a, 1f, and 1g into 2b-d led to potency increases revealing compounds with 
encouraging cytotoxic properties in this assay. The candidate 2b displayed the maximum 
potency, that is, 2b inhibited up to 70% of various adherent and non-adherent tumor cells 
at 1 µM (Table 4-5, page 70). As well, the selectivity towards malignant cells in contrast 
to normal cells was demonstrated mostly by the analogs 2b (SI >65.5) and 2d (SI >36.3) 
as indicated in Table 4-4. Among other auxiliary binders, two compounds 1g, and 1j 
displayed inhibitory effects at 5 µM toward Jurkat and DU145 cancer cells (Table 4-3, 
page 68). To investigate the selective cytotoxicity of target compounds, the compounds 
were screened towards various normal and cancer cells and the selectivity indicies were 
calculated61 (Table 4-6, page 72). The target compounds 2b-d as well as 2a displayed 
favorable cytotoxicity at low CC50 values. The most potent compounds are 2c (CC50= 14 
µM) and 2d (CC50= 21 µM). However, in terms of selectivity, compound 2d is the lead 
compound (SI > 30.44). Compounds 2b-d as well as 2a display remarkable MDR 
reverting properties62 at 50 µM, especially 2b which displayed the most favorable FAR 
value at 50 µM. At a lower concentration (5 µM), the compounds’ revertant properties 
were also revealed but with lower FAR values (Table 4-7, page 73). Future structural 
modifications should first include the other auxiliary binders in designing novel 
anticancer agents having the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore to improve 
the overall potency. Second, the mechanism of action of the auxiliary binding should also 
be investigated. 
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